

Characterisation of COPD heterogeneity in the ECLIPSE

Respiratory Research

11, 122

DOI: [10.1186/1465-9921-11-122](https://doi.org/10.1186/1465-9921-11-122)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Current Controversies and Future Perspectives in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 507-513.	2.5	98
3	Actualit� dans la prise en charge de la BPCO. Revue Des Maladies Respiratoires Actualites, 2011, 3, 257-265.	0.0	0
4	Quantifying the Extent of Emphysema. Academic Radiology, 2011, 18, 659-660.	1.3	0
5	Quantifying the Extent of Emphysema:. Academic Radiology, 2011, 18, 661-671.	1.3	124
8	Pilot analysis of the plasma metabolite profiles associated with emphysematous Chronic Obstructive Pulmonary Disease phenotype. Biochemical and Biophysical Research Communications, 2011, 413, 588-593.	1.0	32
9	Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. Respiratory Medicine, 2011, 105, S12-S19.	1.3	23
10	The importance of dyspnoea in the diagnosis of chronic obstructive pulmonary disease â€“ a descriptive analysis of a stable cohort in Portugal (SAFE Trial). Revista Portuguesa De Pneumologia, 2011, 17, 131-138.	0.7	7
11	Arguments Against Inhaled Glucocorticoids in COPD by Phenotype Instead of by Severity. Archivos De Bronconeumologia, 2011, 47, 269-270.	0.4	2
12	Spirometry in primary care for case finding and management of chronic obstructive pulmonary disease primary care diagnostic technology update. British Journal of General Practice, 2011, 61, 698-699.	0.7	4
14	Characteristics of Dutch and Swiss primary care COPD patients - baseline data of the ICE COLD ERIC study. Clinical Epidemiology, 2011, 3, 273.	1.5	29
15	Chronic obstructive pulmonary disease prevalence in Lebanon: a cross-sectional descriptive study. Clinical Epidemiology, 2011, 3, 315.	1.5	64
16	Asymptomatic COPD and NICE guidelines. British Journal of General Practice, 2011, 61, 294.2-295.	0.7	1
17	Use of cluster analysis to describe desaturator phenotypes in COPD: correlations between pulmonary function tests and nocturnal oxygen desaturation. International Journal of COPD, 2011, 6, 551.	0.9	6
18	Adjusting for COPD severity in database research: developing and validating an algorithm. International Journal of COPD, 2011, 6, 669.	0.9	6
19	Recommended Reading from the Hospital Clinic (Barcelona, Spain) Pulmonary and Critical Care Fellows. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 482-483.	2.5	0
20	Bronchiectasis in Patients With COPD. Chest, 2011, 140, 1107-1108.	0.4	21
21	Complex systems in pulmonary medicine: a systems biology approach to lung disease. Journal of Applied Physiology, 2011, 110, 1716-1722.	1.2	20
23	Too rapid increase and too much breathlessness are distinct indices of exertional dyspnea in COPD. Respiratory Physiology and Neurobiology, 2011, 176, 32-38.	0.7	6

#	ARTICLE	IF	CITATIONS
25	Glucocorticoides inhalados en la EPOC por fenotipo en lugar de gravedad. Argumentos en contra. Archivos De Bronconeumologia, 2011, 47, 269-270.	0.4	4
26	Impaired health status and care dependency in patients with advanced COPD or chronic heart failure. Quality of Life Research, 2011, 20, 1679-1688.	1.5	72
27	Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respiratory Research, 2011, 12, 136.	1.4	54
28	E pluribus plurima: Multidimensional indices and clinical phenotypes in COPD. Respiratory Research, 2011, 12, 152.	1.4	4
29	Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respiratory Research, 2011, 12, 37.	1.4	86
31	Chronic Obstructive Pulmonary Disease Exacerbations in the COPD Gene Study: Associated Radiologic Phenotypes. Radiology, 2011, 261, 274-282.	3.6	373
32	Novel Outcomes and End Points: Biomarkers in Chronic Obstructive Pulmonary Disease Clinical Trials. Proceedings of the American Thoracic Society, 2011, 8, 350-355.	3.5	28
33	Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ, The, 2011, 342, d2549-d2549.	3.0	234
34	The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1015-1021.	2.5	197
35	Night-time symptoms: a forgotten dimension of COPD. European Respiratory Review, 2011, 20, 183-194.	3.0	182
36	Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. European Respiratory Journal, 2011, 38, 749-751.	3.1	40
37	Physical Activity Is the Strongest Predictor of All-Cause Mortality in Patients With COPD. Chest, 2011, 140, 331-342.	0.4	787
38	Patient Phenotyping and Early Disease Detection in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2011, 8, 338-349.	3.5	18
40	Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Review of Respiratory Medicine, 2011, 5, 647-662.	1.0	128
41	Addressing the Complexity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1129-1137.	2.5	166
42	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192.	13.9	811
43	Chronic cough and sputum production: a clinical COPD phenotype?: Table 1â€“. European Respiratory Journal, 2012, 40, 4-6.	3.1	33
44	Autoreactive T Cells in Human Smokers is Predictive of Clinical Outcome. Frontiers in Immunology, 2012, 3, 267.	2.2	29

#	ARTICLE	IF	CITATIONS
45	Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. <i>Thorax</i> , 2012, 67, 502-508.	2.7	68
46	Chronic obstructive pulmonary disease: consequences beyond the lung. <i>Clinical Medicine</i> , 2012, 12, 71-74.	0.8	24
47	Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case–control study (CONSISTE study). <i>International Journal of COPD</i> , 2012, 7, 679.	0.9	52
48	Systemic Inflammation and Comorbidities in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 43-46.	3.5	58
49	Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 936-937.	2.5	4
50	Metabolic profiling detects biomarkers of protein degradation in COPD patients. <i>European Respiratory Journal</i> , 2012, 40, 345-355.	3.1	128
51	The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. <i>European Respiratory Journal</i> , 2012, 40, 28-36.	3.1	164
52	Annual Change in Pulmonary Function and Clinical Phenotype in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 44-52.	2.5	290
54	Clinical COPD phenotypes identified by cluster analysis: validation with mortality. <i>European Respiratory Journal</i> , 2012, 40, 495-496.	3.1	38
55	Health Status Assessment in Routine Clinical Practice: The Chronic Obstructive Pulmonary Disease Assessment Test Score in Outpatients. <i>Respiration</i> , 2012, 84, 193-199.	1.2	85
56	Chronic Obstructive Pulmonary Disease and Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 74-79.	3.5	32
57	Obesity, airflow limitation, and respiratory symptoms: does it take three to tango?. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 131-133.	2.5	1
58	Bronchoscopic lung volume reduction for emphysema: where next?. <i>European Respiratory Journal</i> , 2012, 39, 1287-1289.	3.1	11
59	1. Epidemiology of COPD. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2012, 101, 1532-1537.	0.0	0
60	Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012, 67, 701-708.	2.7	160
61	Early Identification of Small Airways Disease on Lung Cancer Screening CT: Comparison of Current Air Trapping Measures. <i>Lung</i> , 2012, 190, 629-633.	1.4	56
62	Defining COPD: from simplistic approach to multilateral assessment of COPD. <i>Current Respiratory Care Reports</i> , 2012, 1, 177-182.	0.6	4
63	A propÃ³sito do papel do Indacaterol na patologia obstrutiva das vias aÃ©reas: CONTRA. <i>Revista Portuguesa De Pneumologia</i> , 2012, 18, 8-9.	0.7	2

#	ARTICLE	IF	CITATIONS
64	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 291-297.	1.2	193
66	Muscle weakness, health status and frequency of exacerbations in chronic obstructive pulmonary disease. <i>Postgraduate Medical Journal</i> , 2012, 88, 372-376.	0.9	23
67	The potential for acclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2012, 6, 345-361.	1.0	18
70	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1065-1072.	2.5	353
71	Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study. <i>Respiratory Research</i> , 2012, 13, 85.	1.4	43
72	Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 100.	1.0	41
73	Is The CAT Questionnaire Sensitive To Changes In Health Status In Patients With Severe COPD Exacerbations?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 492-498.	0.7	70
74	BODE-index, modified BODE-index and ADO-score in Chronic Obstructive Pulmonary Disease: Relationship with COPD phenotypes and CT lung density changes. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 297-304.	0.7	19
75	The Impact of Ischemic Heart Disease on Symptoms, Health Status, and Exacerbations in Patients With COPD. <i>Chest</i> , 2012, 141, 851-857.	0.4	89
76	Bronchiectasis in COPD patients. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2012, 61, 307-312.	0.1	18
77	Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 155-161.	2.5	946
78	Epidemiology of comorbidities in chronic obstructive pulmonary disease: clusters, phenotypes and outcomes. <i>Italian Journal of Medicine</i> , 2012, 6, 276-284.	0.2	9
79	An omics strategy for discovering pulmonary biomarkers potentially relevant to the evaluation of tobacco products. <i>Biomarkers in Medicine</i> , 2012, 6, 849-860.	0.6	8
80	Contribution of the Environment and Comorbidities to Chronic Obstructive Pulmonary Disease Phenotypes. <i>Medical Clinics of North America</i> , 2012, 96, 713-727.	1.1	36
81	Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. <i>Molecular BioSystems</i> , 2012, 8, 3125.	2.9	94
82	Role of Exercise in Testing and in Therapy of COPD. <i>Medical Clinics of North America</i> , 2012, 96, 753-766.	1.1	15
83	Physical inactivity in COPD and increased patient perception of dyspnea. <i>International Journal of COPD</i> , 2012, 7, 743.	0.9	46
84	Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. <i>International Journal of COPD</i> , 2012, 7, 697.	0.9	123

#	ARTICLE	IF	CITATIONS
86	The relationship between lung function impairment and quantitative computed tomography in chronic obstructive pulmonary disease. <i>European Radiology</i> , 2012, 22, 120-128.	2.3	56
87	Quantitative Computed Tomography in COPD: Possibilities and Limitations. <i>Lung</i> , 2012, 190, 133-145.	1.4	107
88	Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice. <i>Respirology</i> , 2012, 17, 422-431.	1.3	69
89	Pathophysiology Updates for Chronic Obstructive Pulmonary Disease. <i>Current Respiratory Care Reports</i> , 2013, 2, 139-144.	0.6	2
90	COPD and gender differences: an update. <i>Translational Research</i> , 2013, 162, 208-218.	2.2	168
91	The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis. <i>BMC Pulmonary Medicine</i> , 2013, 13, 40.	0.8	47
92	Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. <i>BMC Pulmonary Medicine</i> , 2013, 13, 35.	0.8	79
93	RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. <i>BMC Pulmonary Medicine</i> , 2013, 13, 17.	0.8	30
94	COPD and disease-specific health status in a working population. <i>Respiratory Research</i> , 2013, 14, 61.	1.4	33
95	Pharmacogenetics of chronic obstructive pulmonary disease. <i>Pharmacogenomics</i> , 2013, 14, 1215-1225.	0.6	8
96	Bronchial epithelium as a target for innovative treatments in asthma. , 2013, 140, 290-305.		106
98	Osteoporosis in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 397-410.	1.0	34
99	Bronchiectasis in Older Patients with Chronic Obstructive Pulmonary Disease. <i>Drugs and Aging</i> , 2013, 30, 215-225.	1.3	13
100	Vitamin D, vitamin D binding protein, lung function and structure in COPD. <i>Respiratory Medicine</i> , 2013, 107, 1578-1588.	1.3	42
101	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2013, 107, 1376-1384.	1.3	328
102	Chronic obstructive pulmonary disease and exacerbations: Patient insights from the global Hidden Depths of COPD survey. <i>BMC Pulmonary Medicine</i> , 2013, 13, 54.	0.8	58
103	Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. <i>BMC Pulmonary Medicine</i> , 2013, 13, 51.	0.8	96
104	Factors associated with change in exacerbation frequency in COPD. <i>Respiratory Research</i> , 2013, 14, 79.	1.4	58

#	ARTICLE	IF	CITATIONS
105	Computer quantification of airway collapse on forced expiration to predict the presence of emphysema. <i>Respiratory Research</i> , 2013, 14, 131.	1.4	25
106	Non-“Cystic Fibrosis Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 647-656.	2.5	308
107	The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 367-377.	0.7	67
108	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 347-365.	2.5	7,792
109	GOLD 2011 disease severity classification in COPD Gene: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2013, 1, 43-50.	5.2	209
110	Factor analysis in predominantly severe COPD: Identification of disease heterogeneity by easily measurable characteristics. <i>Respiratory Medicine</i> , 2013, 107, 1939-1947.	1.3	6
111	P38 inhibition in COPD; cautious optimism. <i>Thorax</i> , 2013, 68, 705-706.	2.7	19
112	Heterogeneity in clinical characteristics and co-morbidities in dyspneic individuals with COPD GOLD D: Findings of the DICES trial. <i>Respiratory Medicine</i> , 2013, 107, 1186-1194.	1.3	30
113	Revealing the complexity of chronic obstructive pulmonary disease. <i>Translational Research</i> , 2013, 162, 203-207.	2.2	4
114	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine</i> , 2013, 1, 129-136.	5.2	224
115	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 382-386.	2.5	257
116	Diagnosis of Chronic Obstructive Pulmonary Disease, simpler is better Complexity and simplicity. <i>European Journal of Internal Medicine</i> , 2013, 24, 195-198.	1.0	4
117	Impact of comorbidities on COPD-specific health-related quality of life. <i>Respiratory Medicine</i> , 2013, 107, 233-241.	1.3	103
118	The Rapid FEV1 Decline in Chronic Obstructive Pulmonary Disease Is Associated with Predominant Emphysema: A Longitudinal Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 55-61.	0.7	21
119	Rationale for Earlier Treatment in COPD: A Systematic Review of Published Literature in Mild-to-Moderate COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 79-103.	0.7	41
120	Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2013, 107, 724-731.	1.3	106
121	FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. <i>European Respiratory Journal</i> , 2013, 42, 1391-1401.	3.1	87
122	Clusters of Comorbidities Based on Validated Objective Measurements and Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 728-735.	2.5	657

#	ARTICLE	IF	CITATIONS
123	Chronic Bronchitis and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 228-237.	2.5	334
124	Advances in airway clearance technologies for chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2013, 7, 673-685.	1.0	8
125	Club Cell Protein 16 and Disease Progression in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1413-1419.	2.5	121
126	Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Annals of Medicine, 2013, 45, 291-300.	1.5	98
127	Four types of coping with COPD-induced breathlessness in daily living: a grounded theory study. Journal of Research in Nursing, 2013, 18, 520-541.	0.3	9
128	Response to: Oba, Y. and Lone, N. (2013) Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis: 13(4). Therapeutic Advances in Respiratory Disease, 2013, 7, 247-249.	1.0	1
129	Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. Annals of Nutrition and Metabolism, 2013, 63, 239-247.	1.0	46
130	Echocardiographic abnormalities in patients with COPD at their first hospital admission. European Respiratory Journal, 2013, 41, 784-791.	3.1	95
131	Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open, 2013, 3, e001838.	0.8	22
132	Lungs, Bone Marrow, and Adipose Tissue. A Network Approach to the Pathobiology of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1396-1406.	2.5	32
133	The Search for Distinct and Clinically Useful Phenotypes in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1045-1046.	2.5	8
134	What Is Chronic Obstructive Pulmonary Disease Anyway?. Continua, Categories, Cut Points, and Moving beyond Spirometry. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1036-1037.	2.5	19
135	Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respiratory Research, 2013, 14, 116.	1.4	65
136	The COPD control panel: towards personalised medicine in COPD. Thorax, 2013, 68, 687-690.	2.7	96
137	â€œThe ABC of GOLD A-B-C-Dâ€• European Respiratory Journal, 2013, 42, 1166-1168.	3.1	4
138	Dynamic Data During Hypotensive Episode Improves Mortality Predictions Among Patients With Sepsis and Hypotension*. Critical Care Medicine, 2013, 41, 954-962.	0.4	53
139	Chronic obstructive pulmonary disease and bronchiectasis. Current Opinion in Pulmonary Medicine, 2013, 19, 133-139.	1.2	32
140	Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. European Respiratory Journal, 2013, 42, 647-654.	3.1	153

#	ARTICLE	IF	CITATIONS
141	Comorbidities of COPD. <i>European Respiratory Review</i> , 2013, 22, 454-475.	3.0	353
142	Risk Factors and Comorbidities in the Preclinical Stages of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 30-38.	2.5	93
143	How should we define and classify exacerbations in chronic obstructive pulmonary disease?. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 33-41.	1.0	12
145	Cough and sputum production in COPD patients: clinical phenotype or markers of disease activity?. <i>International Journal of Clinical Practice</i> , 2013, 67, 1218-1219.	0.8	4
146	Nutritional status, gender and marital status in patients with chronic obstructive pulmonary disease. <i>Journal of Clinical Nursing</i> , 2013, 22, 2822-2829.	1.4	12
147	Phenotypes and Disease Characterization in Chronic Obstructive Pulmonary Disease. Toward the Extinction of Phenotypes?. <i>Annals of the American Thoracic Society</i> , 2013, 10, S125-S130.	1.5	42
148	Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. <i>International Journal of Clinical Practice</i> , 2013, 67, 1294-1301.	0.8	35
149	HLA Distribution in COPD Patients. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 138-146.	0.7	15
150	Inhaled corticosteroids for chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2489-2499.	0.9	28
151	Integrated disease management interventions for patients with chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2013, , CD009437.	1.5	168
152	Immune response in chronic obstructive pulmonary disease. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 821-833.	1.3	39
153	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013, 42, 636-646.	3.1	164
154	Optimizing the management of chronic obstructive pulmonary disease: applying the GOLD strategy. <i>Clinical Practice (London, England)</i> , 2013, 10, 481-492.	0.1	3
155	Acute and chronic inflammatory responses induced by smoking in individuals susceptible and non-susceptible to development of COPD: from specific disease phenotyping towards novel therapy. Protocol of a cross-sectional study. <i>BMJ Open</i> , 2013, 3, e002178.	0.8	33
156	Does Spirometry Still Measure Up in the Diagnosis of COPD?. <i>Chest</i> , 2013, 143, 276-277.	0.4	1
157	Symptom variability in COPD: a narrative review. <i>International Journal of COPD</i> , 2013, 8, 231.	0.9	52
158	Portuguese-language version of the COPD Assessment Test: validation for use in Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2013, 39, 402-408.	0.4	59
159	Higher Risk of Wheeze in Female than Male Smokers. Results from the Swedish GA2LEN Study. <i>PLoS ONE</i> , 2013, 8, e54137.	1.1	18

#	ARTICLE	IF	CITATIONS
160	Relationships between Values of Antibodies to Several Connective Tissue Disease Autoantigens and Pulmonary Function in a Japanese General Population: The Takahata Study. PLoS ONE, 2013, 8, e81678.	1.1	6
161	A Lower Level of Forced Expiratory Volume in 1 Second Is a Risk Factor for All-Cause and Cardiovascular Mortality in a Japanese Population: The Takahata Study. PLoS ONE, 2013, 8, e83725.	1.1	38
162	Chronic Obstructive Pulmonary Disease: More Imaging, More Phenotyping...Better Care?. Canadian Respiratory Journal, 2013, 20, 90-90.	0.8	2
163	COPD management: role of symptom assessment in routine clinical practice. International Journal of COPD, 2013, 8, 461.	0.9	49
164	Characteristics of stable chronic obstructive pulmonary disease patients in the pulmonology clinics of seven Asian cities. International Journal of COPD, 2013, 8, 31.	0.9	22
165	Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment. Monaldi Archives for Chest Disease, 2013, 79, .	0.3	0
166	Two cases of COPD benefitting from therapy with roflumilast. Monaldi Archives for Chest Disease, 2013, 79, .	0.3	2
167	Cost of Non-Respiratory Drugs in Copd. Academic Journal of Interdisciplinary Studies, 2013, , .	0.3	0
168	The role of microparticles in chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 303.	0.9	40
169	Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. International Journal of COPD, 2014, 9, 501.	0.9	122
170	Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. International Journal of COPD, 2014, 9, 1145.	0.9	94
171	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 23-34.	0.5	76
172	The concept of control of COPD in clinical practice. International Journal of COPD, 2014, 9, 1397.	0.9	30
173	A telehealth program for self-management of COPD exacerbations and promotion of an active lifestyle: a pilot randomized controlled trial. International Journal of COPD, 2014, 9, 935.	0.9	148
174	New developments in the assessment of COPD: early diagnosis is key. International Journal of COPD, 2014, 9, 277.	0.9	53
175	Epidemiology and clinical impact of major comorbidities in patients with COPD. International Journal of COPD, 2014, 9, 871.	0.9	274
176	Distinguishing adult-onset asthma from COPD: a review and a new approach. International Journal of COPD, 2014, 9, 945.	0.9	58
177	Study Design and Outcomes of Korean Obstructive Lung Disease (KOLD) Cohort Study. Tuberculosis and Respiratory Diseases, 2014, 76, 169.	0.7	49

#	ARTICLE	IF	CITATIONS
178	Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. The Cochrane Library, 2014, , CD006897.	1.5	60
179	Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax, 2014, 69, 709-717.	2.7	70
180	DNAH5 is associated with total lung capacity in chronic obstructive pulmonary disease. Respiratory Research, 2014, 15, 97.	1.4	33
181	Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulmonary Medicine, 2014, 14, 164.	0.8	55
182	Integrative genomics of chronic obstructive pulmonary disease. Biochemical and Biophysical Research Communications, 2014, 452, 276-286.	1.0	41
183	Genome-Wide Study of Percent Emphysema on Computed Tomography in the General Population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 408-418.	2.5	87
184	Identification of Clinical Phenotypes Using Cluster Analyses in COPD Patients with Multiple Comorbidities. BioMed Research International, 2014, 2014, 1-9.	0.9	55
185	Network medicine, multimorbidity and the lung in the elderly. European Respiratory Journal, 2014, 44, 775-788.	3.1	63
186	A divisive Shuffling Approach (ViStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. BMC Systems Biology, 2014, 8, S8.	3.0	24
187	Moving Towards Patient-Centered Medicine for COPD Management: Multidimensional Approaches versus Phenotype-Based Medicine—A Critical View. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 591-602.	0.7	25
188	Assessment of depression in patients with chronic obstructive pulmonary disease. Kontakt, 2014, 16, e203-e208.	0.1	0
189	Disturbed Intestinal Integrity in Patients With COPD. Chest, 2014, 145, 245-252.	0.4	130
191	Cluster analysis in the COPD Gene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax, 2014, 69, 416-423.	2.7	128
193	Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. British Journal of Clinical Pharmacology, 2014, 78, 282-300.	1.1	28
194	Clinical characteristics and airway inflammation profile of COPD persistent sputum producers. Respiratory Medicine, 2014, 108, 1761-1770.	1.3	37
196	Cognitive function in chronic obstructive pulmonary disease: Relationship to global initiative for chronic obstructive lung disease 2011 categories. Respiriology, 2014, 19, 873-880.	1.3	24
197	AIMAR survey on COPD phenotypes. Multidisciplinary Respiratory Medicine, 2014, 9, 16.	0.6	3
198	COPD assessment: I, II, III, IV and/or A, B, C, D. European Respiratory Journal, 2014, 43, 949-950.	3.1	8

#	ARTICLE	IF	CITATIONS
199	Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. <i>BMC Pulmonary Medicine</i> , 2014, 14, 163.	0.8	51
200	Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. <i>BMC Systems Biology</i> , 2014, 8, 78.	3.0	31
201	Systems biology approach for subtyping asthma; where do we stand now?. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 17-22.	1.2	5
202	Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter?. <i>European Respiratory Review</i> , 2014, 23, 131-141.	3.0	95
203	The distribution of COPD in UK general practice using the new GOLD classification. <i>European Respiratory Journal</i> , 2014, 43, 993-1002.	3.1	62
204	Comorbidity in chronic obstructive pulmonary disease. Related to disease severity?. <i>International Journal of COPD</i> , 2014, 9, 1307.	0.9	33
205	The Saudi guidelines for the diagnosis and management of copd. <i>Annals of Thoracic Medicine</i> , 2014, 9, 55.	0.7	38
206	An Integrated therapeutic approach: do COPD comorbidities justify it?. <i>Revista Portuguesa De Pneumologia</i> , 2014, 20, 3-4.	0.7	1
207	Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 267-276.	5.2	149
208	Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion. <i>Respiratory Research</i> , 2014, 15, 2.	1.4	23
209	Co-morbidities in patients with gold stage 4 chronic obstructive pulmonary disease. <i>Revista Portuguesa De Pneumologia</i> , 2014, 20, 5-11.	0.7	21
210	Relationship between femur neck bone mineral density and prevalent chronic obstructive pulmonary disease (COPD) or COPD mortality in older non-Hispanic white adults from NHANES III. <i>Osteoporosis International</i> , 2014, 25, 1043-1052.	1.3	14
211	Coronary artery disease concomitant with chronic obstructive pulmonary disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 93-102.	1.7	58
212	Comorbidities and Systemic Effects of Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2014, 35, 101-130.	0.8	71
213	A Population-Based Cohort Study on Chronic Obstructive Pulmonary Disease in Latin America: Methods and Preliminary Results. The PLATINO Study Phase II. <i>Archivos De Bronconeumología</i> , 2014, 50, 10-17.	0.4	10
214	Biomarkers in COPD. <i>Clinics in Chest Medicine</i> , 2014, 35, 131-141.	0.8	48
215	Risk factors for chronic mucus hypersecretion in individuals with and without COPD: influence of smoking and job exposure on CMH. <i>Occupational and Environmental Medicine</i> , 2014, 71, 346-352.	1.3	17
216	Azithromycin for patients with frequent COPD exacerbations. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 340-341.	5.2	2

#	ARTICLE	IF	CITATIONS
217	New Drug Therapies for COPD. <i>Clinics in Chest Medicine</i> , 2014, 35, 219-239.	0.8	13
218	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , 2014, 69, 718-723.	2.7	151
219	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2014, 108, 1647-1654.	1.3	22
220	The concept of control in COPD: a new proposal for optimising therapy. <i>European Respiratory Journal</i> , 2014, 44, 1072-1075.	3.1	31
221	Chronic obstructive pulmonary disease and exacerbations: clinician insights from the global Hidden Depths of COPD survey. <i>Current Medical Research and Opinion</i> , 2014, 30, 667-684.	0.9	13
222	Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPD Gene. <i>Respiratory Medicine</i> , 2014, 108, 1469-1480.	1.3	24
223	Advanced glycation end products in the skin are enhanced in COPD. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1149-1156.	1.5	34
224	The path to personalised medicine in COPD. <i>Thorax</i> , 2014, 69, 857-864.	2.7	158
225	COPD-related Bronchiectasis; Independent Impact on Disease Course and Outcomes. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 605-614.	0.7	76
226	Personalized medicine in COPD treatment. <i>Current Respiratory Care Reports</i> , 2014, 3, 133-139.	0.6	1
227	Impact of self-reported Gastroesophageal reflux disease in subjects from COPD Gene cohort. <i>Respiratory Research</i> , 2014, 15, 62.	1.4	61
228	Phenotyping of COPD: challenges and next steps. <i>Lancet Respiratory Medicine</i> , 2014, 2, 172-174.	5.2	6
229	A possible link between increased metabolic activity of fat tissue and aortic wall inflammation in subjects with COPD. A retrospective 18F-FDG-PET/CT pilot study. <i>Respiratory Medicine</i> , 2014, 108, 883-890.	1.3	21
230	Comorbilidades em doentes com doena pulmonar obstrutiva crnica estdio IV. <i>Revista Portuguesa De Pneumologia</i> , 2014, 20, 5-11.	0.7	22
231	CT quantification of emphysema: Is semi-quantitative scoring a reliable enough method?. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2014, 45, 673-678.	0.3	7
232	Estudio de cohorte de base poblacional sobre la enfermedad pulmonar obstructiva crnica en Latinoamrica: mtodos y resultados preliminares. Fase II del estudio PLATINO. <i>Archivos De Bronconeumologia</i> , 2014, 50, 10-17.	0.4	13
233	Longitudinal HRQoL shows divergent trends and identifies constant decliners in asthma and COPD. <i>Respiratory Medicine</i> , 2014, 108, 463-471.	1.3	11
235	Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. <i>Respiratory Medicine</i> , 2014, 108, 129-135.	1.3	48

#	ARTICLE	IF	CITATIONS
236	The use of health status questionnaires in the management of chronic obstructive pulmonary disease patients in clinical practice. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 479-491.	1.0	8
237	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1022-1030.	2.5	130
238	13. Comorbidities in Patients with COPD. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2014, 103, 121a-121a.	0.0	0
240	Cytokine inhibition in the treatment of COPD. <i>International Journal of COPD</i> , 2014, 9, 397.	0.9	88
241	Clinical issues of mucus accumulation in COPD. <i>International Journal of COPD</i> , 2014, 9, 139.	0.9	83
242	Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management. <i>Journal of Translational Medicine</i> , 2014, 12, S3.	1.8	34
243	The prevalence of COPD co-morbidities in Serbia: results of a national survey. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14008.	1.1	16
244	Rapid Lung Function Decline in Smokers Is a Risk Factor for COPD and Is Attenuated by Angiotensin-Converting Enzyme Inhibitor Use. <i>Chest</i> , 2014, 145, 695-703.	0.4	60
245	Obstructive Lung Disease in Mexican Americans and Non-Hispanic Whites. <i>Chest</i> , 2014, 145, 282-289.	0.4	16
246	Smoking Cessation in COPD Causes a Transient Improvement in Spirometry and Decreases Micronodules on High-Resolution CT Imaging. <i>Chest</i> , 2014, 145, 1006-1015.	0.4	18
247	COPD: early diagnosis and treatment to slow disease progression. <i>International Journal of Clinical Practice</i> , 2015, 69, 336-349.	0.8	98
248	Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: A hospital-based cross-section study. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 155-160.	1.0	12
249	Impact of cardiovascular comorbidities on COPD Assessment Test (CAT) and its responsiveness to pulmonary rehabilitation in patients with moderate to very severe COPD: protocol of the Chance study. <i>BMJ Open</i> , 2015, 5, e007536.	0.8	27
250	Patterns of Emphysema Heterogeneity. <i>Respiration</i> , 2015, 90, 402-411.	1.2	35
251	The clinical relevance of the emphysema-hyperinflated phenotype in COPD. <i>COPD Research and Practice</i> , 2015, 2, .	0.7	13
252	Chronic obstructive pulmonary disease and diabetes. <i>COPD Research and Practice</i> , 2015, 1, .	0.7	27
253	Diagnosis in chronic obstructive pulmonary disease—Too little, too late? <i>Chronic Respiratory Disease</i> , 2015, 12, 281-283.	1.0	3
254	Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 22.	0.6	8

#	ARTICLE	IF	CITATIONS
255	Effects of Omega-3 fatty acids in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1086-1092.	1.0	19
256	Bronchiectasis Phenotype in COPD Patients. <i>Clinical Pulmonary Medicine</i> , 2015, 22, 123-127.	0.3	3
257	Functional Capacity, Health Status, and Inflammatory Biomarker Profile in a Cohort of Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2015, 35, 348-355.	1.2	8
258	Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units. <i>International Journal of COPD</i> , 2015, 10, 173.	0.9	69
259	Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. <i>International Journal of COPD</i> , 2015, 10, 399.	0.9	33
260	Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population. <i>International Journal of COPD</i> , 2015, 10, 565.	0.9	1
261	What pulmonologists think about the asthma‐COPD overlap syndrome. <i>International Journal of COPD</i> , 2015, 10, 1321.	0.9	35
262	The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units. <i>International Journal of COPD</i> , 2015, 10, 2327.	0.9	23
263	Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey. <i>International Journal of COPD</i> , 2015, 10, 1571.	0.9	18
264	A bibliometric analysis of the 100 most influential papers on COPD. <i>International Journal of COPD</i> , 2015, 10, 667.	0.9	9
265	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 549.	0.9	26
266	Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls. <i>International Journal of COPD</i> , 2015, 10, 185.	0.9	19
267	Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2015, 10, e0123626.	1.1	14
268	Socio-Economic and Clinical Factors as Predictors of Disease Evolution and Acute Events in COPD Patients. <i>PLoS ONE</i> , 2015, 10, e0135116.	1.1	5
269	Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. <i>International Journal of COPD</i> , 2015, 10, 1465.	0.9	96
270	Chronic obstructive pulmonary disease severity is associated with severe pneumonia. <i>Annals of Thoracic Medicine</i> , 2015, 10, 105.	0.7	15
271	Association between inhaler use and risk of haemoptysis in patients with non‐cystic fibrosis bronchiectasis. <i>Respirology</i> , 2015, 20, 1213-1221.	1.3	7
272	<sc>COPD</sc> and its comorbidities: Impact, measurement and mechanisms. <i>Respirology</i> , 2015, 20, 1160-1171.	1.3	182

#	ARTICLE	IF	CITATIONS
273	Prevalence and underdiagnosis of airway obstruction among middle-aged adults in northern France: The ELISABET study 2011â€“2013. <i>Respiratory Medicine</i> , 2015, 109, 1553-1561.	1.3	45
274	Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 89-92.	1.0	30
275	Chronic obstructive pulmonary disease: The golden decade. Implications for the diagnosis, prevention and treatment of chronic obstructive pulmonary disease. <i>Medicina Cl�nica (English Edition)</i> , 2015, 144, 507-513.	0.1	1
276	Survival in Patients with Advanced Non-cystic Fibrosis Bronchiectasis Versus Cystic Fibrosis on the Waitlist for Lung Transplantation. <i>Lung</i> , 2015, 193, 933-938.	1.4	14
277	Persistent endothelial dysfunction turns the frequent exacerbator COPD from respiratory disorder into a progressive pulmonary and systemic vascular disease. <i>Medical Hypotheses</i> , 2015, 84, 155-158.	0.8	25
278	Obvious emphysema on computed tomography during an acute exacerbation of chronic obstructive pulmonary disease predicts a poor prognosis. <i>Internal Medicine Journal</i> , 2015, 45, 517-526.	0.5	10
279	Limitation of Activities of Daily Living and Quality of Life Based on COPD Combined Classification. <i>Respiratory Care</i> , 2015, 60, 388-398.	0.8	24
280	Assessment of the internal structure of GOLD 2011 system. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 30, 87-92.	1.1	2
281	Physical Activity and the Frequency of Acute Exacerbations in Patients with Chronic Obstructive Pulmonary Disease. <i>Lung</i> , 2015, 193, 63-70.	1.4	7
282	GOLD B-C-D groups or GOLD II-III-IV grades. <i>Chronic Respiratory Disease</i> , 2015, 12, 102-110.	1.0	13
283	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 303-312.	1.5	126
284	Occupational Exposures and Chronic Obstructive Pulmonary Disease. Causality Established, Time to Focus on Effect and Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 499-501.	2.5	5
285	Strategies for Reducing the Risk of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 103-111.	1.0	11
286	Breathlessness or Health Status in Chronic Obstructive Pulmonary Disease: The Impact of Different Definitions. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 115-125.	0.7	22
287	Patient-reported outcomes and considerations in the management of COPD: focus on acclidinium. <i>Patient Preference and Adherence</i> , 2015, 9, 95.	0.8	7
288	Validation of the GOLD 2013 classification in predicting exacerbations and mortality in Taiwanese patients with chronic obstructive pulmonary disease. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 1258-1266.	0.8	7
289	Molecular and clinical disease of comorbidities in exacerbated COPD patients. <i>European Respiratory Journal</i> , 2015, 46, 1001-1010.	3.1	32
290	Clinical and prognostic heterogeneity of C and D GOLD groups. <i>European Respiratory Journal</i> , 2015, 46, 250-254.	3.1	11

#	ARTICLE	IF	CITATIONS
291	A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with $\leq 2\%$ and $> 2\%$ blood eosinophils. <i>Respiratory Medicine</i> , 2015, 109, 860-869.	1.3	28
292	Integrative Analysis of DNA Methylation and Gene Expression Data Identifies EPAS1 as a Key Regulator of COPD. <i>PLoS Genetics</i> , 2015, 11, e1004898.	1.5	82
293	Causes of chronic productive cough: An approach to management. <i>Respiratory Medicine</i> , 2015, 109, 1105-1113.	1.3	35
294	The Relationship of Educational Attainment with Pulmonary Emphysema and Airway Wall Thickness. <i>Annals of the American Thoracic Society</i> , 2015, 12, 813-820.	1.5	6
295	Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. <i>Lancet, The</i> , 2015, 385, 1789-1798.	6.3	209
296	Fracture prevention in COPD patients; a clinical 5-step approach. <i>Respiratory Research</i> , 2015, 16, 32.	1.4	21
297	Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. <i>Respiratory Medicine</i> , 2015, 109, 870-881.	1.3	77
298	Chronic Obstructive Pulmonary Disease Phenotypes. Past, Present, and Future. <i>Annals of the American Thoracic Society</i> , 2015, 12, 289-290.	1.5	4
299	Bronchiectasis in COPD: A New Phenotype of COPD with Particular Attention. <i>Journal of Pulmonary & Respiratory Medicine</i> , 2015, 05, .	0.1	1
300	Management of bronchiectasis in adults. <i>European Respiratory Journal</i> , 2015, 45, 1446-1462.	3.1	220
301	Chronic Obstructive Pulmonary Disease: Pulmonary Function and CT Lung Attenuation Do Not Show Linear Correlation. <i>Radiology</i> , 2015, 276, 571-578.	3.6	21
302	Hospitalized Exacerbations of COPD. <i>Chest</i> , 2015, 147, 999-1007.	0.4	269
303	Physiologic Characterization of the Chronic Bronchitis Phenotype in GOLD Grade IB COPD. <i>Chest</i> , 2015, 147, 1235-1245.	0.4	32
304	The chronic bronchitis phenotype in chronic obstructive pulmonary disease. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 133-141.	1.2	69
305	Bronchiectasis. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 272-277.	1.2	4
306	Delay in diagnosis of chronic obstructive pulmonary disease. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 121-126.	1.2	17
307	Chronic Obstructive Pulmonary Disease and Left Ventricle. <i>Archivos De Bronconeumologia</i> , 2015, 51, 227-234.	0.4	11
308	Prevalence of Co-morbidities and Severity of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 390-394.	0.7	16

#	ARTICLE	IF	CITATIONS
309	Comparison of Global Initiative for Chronic Obstructive Pulmonary Disease 2013 Classification and Body Mass Index, Airflow Obstruction, Dyspnea, and Exacerbations Index in Predicting Mortality and Exacerbations in Elderly Adults with Chronic Obstructive Pulmonary Disease. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 244-250.	1.3	14
310	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	2.5	166
311	Large trials, new knowledge: the changing face of COPD management. <i>European Respiratory Journal</i> , 2015, 45, 1692-1703.	3.1	22
312	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	3.1	138
313	Causes of Death Associated With Prolonged TV Viewing. <i>American Journal of Preventive Medicine</i> , 2015, 49, 811-821.	1.6	54
314	Diagnostic approach to bronchiectasis. <i>Current Pulmonology Reports</i> , 2015, 4, 191-197.	0.5	1
315	Alterations in the sputum proteome and transcriptome in smokers and early-stage COPD subjects. <i>Journal of Proteomics</i> , 2015, 128, 306-320.	1.2	72
316	Reply: The association between chronic obstructive pulmonary disease and dementia: a population-based retrospective cohort study. <i>European Journal of Neurology</i> , 2015, 22, e71.	1.7	1
317	Chronic bronchitis leads to accelerated hyperinflation in COPD patients during exercise. <i>Respirology</i> , 2015, 20, 618-625.	1.3	7
318	Physician-Patient Concordance in Pharmacological Management of Patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 473-483.	0.7	5
319	Oxygen-weighted Hyperpolarized ³ He MR Imaging: A Short-term Reproducibility Study in Human Subjects. <i>Radiology</i> , 2015, 277, 247-258.	3.6	7
320	Differential response to pulmonary rehabilitation in COPD: multidimensional profiling. <i>European Respiratory Journal</i> , 2015, 46, 1625-1635.	3.1	180
321	A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2015, 12, 988-996.	1.5	37
322	Clinical and Immunological Factors in Emphysema Progression. Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1171-1178.	2.5	41
323	Comorbidity in chronic obstructive pulmonary disease. <i>Respiratory Investigation</i> , 2015, 53, 249-258.	0.9	47
324	Bronchiectasis in adults: epidemiology, assessment of severity and prognosis. <i>Current Pulmonology Reports</i> , 2015, 4, 142-151.	0.5	1
325	Updates in the management of stable chronic obstructive pulmonary disease. <i>Postgraduate Medicine</i> , 2015, 127, 758-770.	0.9	7
327	Enfermedad pulmonar obstructiva crónica y ventrículo izquierdo. <i>Archivos De Bronconeumología</i> , 2015, 51, 227-234.	0.4	17

#	ARTICLE	IF	CITATIONS
328	Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD. <i>European Respiratory Journal</i> , 2015, 45, 60-75.	3.1	19
329	Risk factors and early origins of chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2015, 385, 899-909.	6.3	410
330	Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease. <i>Chinese Medical Journal</i> , 2016, 129, 2017-2019.	0.9	4
331	Once daily Long-acting beta2 -agonists/Inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2016, , .	1.5	2
332	Determinants for changing the treatment of COPD: a regression analysis from a clinical audit. <i>International Journal of COPD</i> , 2016, 11, 1171.	0.9	14
333	Chronic bronchitis is an independently associated factor for more symptom and high-risk groups. <i>International Journal of COPD</i> , 2016, 11, 1335.	0.9	8
334	Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD. <i>International Journal of COPD</i> , 2016, 11, 1403.	0.9	7
335	Interpreting patient-reported outcomes from clinical trials in COPD: a discussion. <i>International Journal of COPD</i> , 2016, Volume 11, 3069-3078.	0.9	21
336	Effects of aclidinium on determinants of COPD severity: symptoms and quality of life. <i>International Journal of COPD</i> , 2016, Volume 11, 3043-3050.	0.9	5
337	Sex differences of COPD phenotypes in nonsmoking patients. <i>International Journal of COPD</i> , 2016, Volume 11, 1657-1662.	0.9	27
338	Characteristics of Patients with Chronic Obstructive Pulmonary Disease at the First Visit to a Pulmonary Medical Center in Korea: The KOrea COPd Subgroup Study Team Cohort. <i>Journal of Korean Medical Science</i> , 2016, 31, 553.	1.1	62
339	Lung perfusion and emphysema distribution affect the outcome of endobronchial valve therapy. <i>International Journal of COPD</i> , 2016, 11, 1245.	0.9	20
340	Lower diffusing capacity with chronic bronchitis predicts higher risk of acute exacerbation in chronic obstructive lung disease. <i>Journal of Thoracic Disease</i> , 2016, 8, 1274-1282.	0.6	16
341	Evaluation of symptomatic patients without airflow obstruction: back to the future. <i>Journal of Thoracic Disease</i> , 2016, 8, E1657-E1660.	0.6	4
342	Impact of current cough on health-related quality of life in patients with COPD. <i>International Journal of COPD</i> , 2016, Volume 11, 2091-2097.	0.9	43
343	Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD. <i>Jornal Brasileiro De Pneumologia</i> , 2016, 42, 179-184.	0.4	13
344	Bronchiectasis in the Last Five Years: New Developments. <i>Journal of Clinical Medicine</i> , 2016, 5, 115.	1.0	16
345	COPD Overlap Syndromes: Asthma and Beyond. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 459-465.	0.5	7

#	ARTICLE	IF	CITATIONS
346	Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. <i>International Journal of COPD</i> , 2016, 11, 123.	0.9	19
347	Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. <i>International Journal of COPD</i> , 2016, 11 Spec Iss, 3.	0.9	63
348	Computed tomography-derived pathological phenotypes in COPD. <i>European Respiratory Journal</i> , 2016, 48, 10-13.	3.1	7
349	Biomass smoke exposure and chronic lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 150-157.	1.2	34
350	Home telemonitoring for patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. <i>BMC Pulmonary Medicine</i> , 2016, 16, 157.	0.8	58
351	The Neutrophil to Lymphocyte Ratio Is Related to Disease Severity and Exacerbation in Patients with Chronic Obstructive Pulmonary Disease. <i>Internal Medicine</i> , 2016, 55, 223-229.	0.3	55
352	Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine. <i>Annals of the American Thoracic Society</i> , 2016, 13, S466-S470.	1.5	20
353	Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. <i>Journal of Interdisciplinary Medicine</i> , 2016, 1, 12-17.	0.1	4
354	Lower extremity and carotid artery disease in COPD. <i>ERJ Open Research</i> , 2016, 2, 00037-2016.	1.1	11
355	Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2016, 2016, CD005074.	1.5	58
356	Pulmonary MRI in Clinical Trials. <i>Medical Radiology</i> , 2016, , 453-478.	0.0	0
357	Prevalence & pattern of respiratory diseases including Tuberculosis in elderly in Ghaziabad " Delhi " NCR. <i>Indian Journal of Tuberculosis</i> , 2016, 63, 236-241.	0.3	4
358	COPD control: Can a consensus be found?. <i>Revista Portuguesa De Pneumologia</i> , 2016, 22, 167-176.	0.7	12
359	Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. <i>European Respiratory Journal</i> , 2016, 48, 92-103.	3.1	46
360	Diagnostic challenges of bronchiectasis. <i>Respiratory Medicine</i> , 2016, 116, 70-77.	1.3	27
361	Recommendations for aetiological diagnosis of bronchiectasis. <i>Revista Portuguesa De Pneumologia</i> , 2016, 22, 222-235.	0.7	13
362	The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 399-406.	0.7	125
363	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. <i>Respiratory Medicine</i> , 2016, 114, 27-37.	1.3	113

#	ARTICLE	IF	CITATIONS
364	Cardiovascular risk, chronic obstructive pulmonary disease and pulmonary rehabilitation. <i>Chronic Respiratory Disease</i> , 2016, 13, 286-294.	1.0	8
365	Prediction and prevention of exacerbations and mortality in patients with COPD. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 739-753.	1.0	15
366	Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 712-718.	1.2	77
367	Global impact of bronchiectasis and cystic fibrosis. <i>Breathe</i> , 2016, 12, 222-235.	0.6	51
368	Choose your outcomes: From the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey. <i>European Journal of Internal Medicine</i> , 2016, 34, 85-88.	1.0	3
369	A multicenter randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of rhubarb in treating acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs. <i>Journal of Traditional Chinese Medical Sciences</i> , 2016, 3, 71-80.	0.1	0
370	Burden of COPD in patients treated in different care settings in the Netherlands. <i>Respiratory Medicine</i> , 2016, 118, 76-83.	1.3	20
371	Biomarkers, the control panel and personalized <scp>COPD</scp> medicine. <i>Respirology</i> , 2016, 21, 24-33.	1.3	42
372	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 541-549.	2.5	73
373	Cell-derived microparticles and the lung. <i>European Respiratory Review</i> , 2016, 25, 266-277.	3.0	41
374	High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study. <i>Respiratory Research</i> , 2016, 17, 125.	1.4	57
375	Oxygen therapy in COPD patients with isolated nocturnal hypoxemia; comparison of quality of life and sleep between bronchitis and emphysema phenotype: A prospective observational study. <i>European Journal of Internal Medicine</i> , 2016, 34, 78-84.	1.0	8
376	An ECLIPSE View of Alpha-1 Antitrypsin Deficiency. <i>Annals of the American Thoracic Society</i> , 2016, 13, S326-S331.	1.5	11
377	Does the Term “Deflators” Reflect More Accurately the Beneficial Effects of Long-acting Bronchodilators in COPD?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 537-539.	0.7	9
378	Sex Difference in Chronic Obstructive Lung Disease. Does it Matter? A Concise Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 799-806.	0.7	19
379	B cells in chronic obstructive pulmonary disease: moving to center stage. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L687-L695.	1.3	83
380	Derivation of a test statistic for emphysema quantification. , 2016, 2016, 1269-1273.		1
381	Single-Breath Washout Tests to Assess Small Airway Disease in COPD. <i>Chest</i> , 2016, 150, 1091-1100.	0.4	29

#	ARTICLE	IF	CITATIONS
382	Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies. <i>Respiratory Medicine</i> , 2016, 117, 154-161.	1.3	124
383	Review of chronic obstructive airway disease patients admitted at Maamoura Chest Hospital from 2009 to 2012. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2016, 65, 49-61.	0.1	2
384	Efficacy of inhaled medications in asthma and COPD related to disease severity. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1719-1727.	2.4	6
385	Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. <i>Clinical and Translational Medicine</i> , 2016, 5, 9.	1.7	13
386	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1483-1493.	2.5	83
387	Effects of dynamic hyperinflation on exercise capacity and quality of life in stable <sc>COPD</sc> patients. <i>Clinical Respiratory Journal</i> , 2016, 10, 579-588.	0.6	6
388	Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. <i>European Respiratory Journal</i> , 2016, 47, 429-460.	3.1	311
389	Personality and Lung Function in Older Adults. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2017, 72, gbv161.	2.4	14
390	COPD subtypes identified by network-based clustering of blood gene expression. <i>Genomics</i> , 2016, 107, 51-58.	1.3	49
391	Computed Tomographic Airway Morphology in Chronic Obstructive Pulmonary Disease. Remodeling or Innate Anatomy?. <i>Annals of the American Thoracic Society</i> , 2016, 13, 4-9.	1.5	16
392	Regional Heterogeneity of Chronic Obstructive Pulmonary Disease Phenotypes: Pulmonary ³He Magnetic Resonance Imaging and Computed Tomography. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 601-609.	0.7	12
393	Understanding COPD: A vision on phenotypes, comorbidities and treatment approach. <i>Revista Portuguesa De Pneumologia</i> , 2016, 22, 101-111.	0.7	23
394	Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature. <i>Multidisciplinary Respiratory Medicine</i> , 2016, 11, 5.	0.6	6
396	Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes. <i>Nitric Oxide - Biology and Chemistry</i> , 2016, 54, 67-72.	1.2	31
397	Incapacity, Handicap, and Oxidative Stress Markers of Male Smokers With and Without COPD. <i>Respiratory Care</i> , 2016, 61, 668-679.	0.8	16
398	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016, 2, 00081-2015.	1.1	133
399	Study Design and Interim Outcomes of Guangzhou Institute of Respiratory Disease COPD Biobank. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 203-213.	0.7	8
400	Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1242-1253.	2.5	99

#	ARTICLE	IF	CITATIONS
401	Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 607-613.	2.5	104
402	Women and COPD. Respiratory Medicine, 2016, , 63-85.	0.1	0
403	Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Translational Research, 2016, 167, 192-203.	2.2	100
404	COPD. , 2016, , 751-766.e7.		2
405	Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. Medical Decision Making, 2017, 37, 453-468.	1.2	24
406	Randomized, dose-finding trial of ghrelin treatment for chronic respiratory failure. Clinical Respiratory Journal, 2017, 11, 496-505.	0.6	4
407	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. Medical Decision Making, 2017, 37, 469-480.	1.2	29
408	Prevalence and impact of urinary incontinence in men with chronic obstructive pulmonary disease: a questionnaire survey. Physiotherapy, 2017, 103, 53-58.	0.2	20
409	Evaluation of the visit frequency and the use of questionnaires and indices for COPD: a national survey from the <sc>O</sc> <sc>S</sc> int study. Clinical Respiratory Journal, 2017, 11, 367-373.	0.6	1
410	Study of cardiovascular diseases in hospitalized AECOPD patients. The Egyptian Journal of Chest Diseases and Tuberculosis, 2017, 66, 17-25.	0.1	3
411	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	1.3	299
412	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 2017, 49, 1700214.	3.1	536
413	Symptoms and the body: Taking the inferential leap. Neuroscience and Biobehavioral Reviews, 2017, 74, 185-203.	2.9	323
414	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	2.5	2,393
415	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.4	173
416	Pharmacological treatment for COPD; GOLD 2017 changes direction. British Journal of Clinical Pharmacology, 2017, 83, 935-937.	1.1	8
417	Understanding COPD-overlap syndromes. Expert Review of Respiratory Medicine, 2017, 11, 285-298.	1.0	47
418	Improvement of metabolic disorders by an EP 2 receptor agonist via restoration of the subcutaneous adipose tissue in pulmonary emphysema. Prostaglandins and Other Lipid Mediators, 2017, 130, 16-22.	1.0	4

#	ARTICLE	IF	CITATIONS
419	Quantitative Assessment of Airway Pathology in Subjects With COPD Using Low-Dose High-Resolution Computed Tomography. <i>Respiratory Care</i> , 2017, 62, 953-962.	0.8	2
420	Applying Systems Medicine in the clinic. <i>Current Opinion in Systems Biology</i> , 2017, 3, 77-87.	1.3	3
421	Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. <i>European Respiratory Journal</i> , 2017, 49, 1601446.	3.1	80
422	Chronic Obstructive Pulmonary Disease and the Risk of Stroke. <i>Annals of the American Thoracic Society</i> , 2017, 14, 754-765.	1.5	21
423	Bronchiectasis and COPD Overlap. <i>Chest</i> , 2017, 151, 1204-1206.	0.4	17
424	Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. <i>Chronic Respiratory Disease</i> , 2017, 14, 377-384.	1.0	126
425	Chronic Obstructive Pulmonary Disease in Women. Is it Different?. <i>Archivos De Bronconeumologia</i> , 2017, 53, 222-227.	0.4	3
426	Enfermedad pulmonar obstructiva crónica en mujeres: ¿somos diferentes?. <i>Archivos De Bronconeumologia</i> , 2017, 53, 222-227.	0.4	10
427	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. <i>Archivos De Bronconeumologia</i> , 2017, 53, 128-149.	0.4	312
428	Phenotyping Before Starting Treatment in COPD?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 367-374.	0.7	22
429	Maximal mid-expiratory flow detects early lung disease in α -antitrypsin deficiency. <i>European Respiratory Journal</i> , 2017, 49, 1602055.	3.1	50
430	Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 18.	1.1	32
431	Spiritual Well-Being and Correlated Factors in Subjects With Advanced COPD or Lung Cancer. <i>Respiratory Care</i> , 2017, 62, 544-549.	0.8	21
433	Symptomatic Assessment of COPD. , 2017, , 75-86.		0
434	A simple algorithm for the identification of clinical COPD phenotypes. <i>European Respiratory Journal</i> , 2017, 50, 1701034.	3.1	53
435	The refined ABCD assessment and non-costly laboratory parameters are outcome predictors in acute exacerbation of COPD. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2017, 66, 599-603.	0.1	4
436	Cardiovascular events in patients with chronic obstructive bronchopulmonary disease. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e23-e29.	0.6	1
437	Right Heart Failure as a Risk for Stroke in Patients with Chronic Obstructive Pulmonary Disease: A Case-Control Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 2988-2993.	0.7	4

#	ARTICLE	IF	CITATIONS
438	Diaphragmatic Thickness Fraction in Subjects at High-Risk for COPD Exacerbations. <i>Respiratory Care</i> , 2017, 62, 1565-1570.	0.8	18
439	Evaluation of symptoms and risks in stable chronic obstructive pulmonary disease patients with radiographic bronchiectasis. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 176-180.	0.9	4
440	The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 27.	1.1	123
441	New treatment options for lower respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1345-1355.	0.9	11
442	Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2017, 50, 1602470.	3.1	70
443	Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. <i>European Respiratory Journal</i> , 2017, 50, 1700621.	3.1	66
444	Importance of GOLD Guidelines for Chronic Obstructive Pulmonary Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1022, 45-52.	0.8	1
445	Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ. <i>Respiratory Medicine</i> , 2017, 130, 1-8.	1.3	6
446	Physical activity in patients with COPD: the impact of comorbidities. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 685-698.	1.0	21
447	Integral Health Status-Based Cluster Analysis in Moderate to Severe COPD Patients Identifies Three Clinical Phenotypes: Relevant for Treatment As Usual and Pulmonary Rehabilitation. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 571-583.	0.8	16
448	Proteomic profiling of peripheral blood neutrophils identifies two inflammatory phenotypes in stable COPD patients. <i>Respiratory Research</i> , 2017, 18, 100.	1.4	18
449	A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2017, 20, 152-162.	0.1	22
450	Improving the Management of COPD in Women. <i>Chest</i> , 2017, 151, 686-696.	0.4	86
451	Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2017, 37, 440-452.	1.2	21
452	Biomarker Development in COPD. <i>Chest</i> , 2017, 151, 455-467.	0.4	36
453	Identifying and treating different phenotypes in COPD. <i>Practice Nursing</i> , 2017, 28, 424-430.	0.1	0
454	Natural history of COPD: gaps and opportunities. <i>ERJ Open Research</i> , 2017, 3, 00117-2017.	1.1	40
455	The effectiveness of a nurse-led illness perception intervention in COPD patients: a cluster randomised trial in primary care. <i>ERJ Open Research</i> , 2017, 3, 00115-2016.	1.1	20

#	ARTICLE	IF	CITATIONS
456	Evaluation of clinical variables according to follow-up times in COPD: results from ON-SINT cohort. European Clinical Respiratory Journal, 2017, 4, 1394132.	0.7	1
457	Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. Journal of Thoracic Disease, 2017, 9, 1144-1154.	0.6	46
458	The COPD Biomarkers Qualification Consortium St George's Respiratory Questionnaire Manuscripts: Output of a Consortium to Advance Drug Development. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 105-107.	0.5	4
459	Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. International Journal of COPD, 2017, Volume 12, 2189-2196.	0.9	43
460	Potential of Health and Demographic Surveillance System in Asthma and Chronic Obstructive Pulmonary Disease Microbiome Research. Frontiers in Public Health, 2017, 5, 196.	1.3	5
461	Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies. International Journal of COPD, 2017, Volume 12, 2593-2610.	0.9	44
462	Bronchiectasis in COPD patients: more than a comorbidity?. International Journal of COPD, 2017, Volume 12, 1401-1411.	0.9	104
463	Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review. International Journal of COPD, 2017, Volume 12, 1867-1876.	0.9	14
464	Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. International Journal of COPD, 2018, Volume 13, 45-56.	0.9	13
465	Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD. International Journal of COPD, 2017, Volume 12, 2629-2638.	0.9	38
466	When is dual bronchodilation indicated in COPD?. International Journal of COPD, 2017, Volume 12, 2291-2305.	0.9	16
467	Exacerbations in COPD Patients with Bronchiectasis. Medical Sciences (Basel, Switzerland), 2017, 5, 7.	1.3	7
468	Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity. International Journal of COPD, 2017, Volume 12, 3301-3310.	0.9	32
469	Gender Differences in Chronic Obstructive Pulmonary Disease’ Current Knowledge and Deficits. , 2017, , 391-400.		1
470	Chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2017, 23, 117-123.	1.2	35
471	Recommendations for the pharmacological treatment of COPD: questions and answers. Jornal Brasileiro De Pneumologia, 2017, 43, 290-301.	0.4	20
472	The EASI model: A first integrative computational approximation to the natural history of COPD. PLoS ONE, 2017, 12, e0185502.	1.1	4
473	Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS ONE, 2017, 12, e0175794.	1.1	47

#	ARTICLE	IF	CITATIONS
474	Implementation of GOLD consensus report in real life: results from the Velletri-Lariano (VELA) cohort. <i>Multidisciplinary Respiratory Medicine</i> , 2017, 12, 18.	0.6	0
475	Changes in definition lead to changes in the clinical characteristics across COPD categories according to GOLD 2017: a national cross-sectional survey in China. <i>International Journal of COPD</i> , 2017, Volume 12, 3095-3102.	0.9	22
476	Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy. <i>International Journal of COPD</i> , 2017, Volume 12, 451-460.	0.9	33
477	Peripheral leukocyte microRNAs as novel biomarkers for COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 1101-1112.	0.9	18
478	Recent advances in the management of chronic obstructive pulmonary disease. <i>F1000Research</i> , 2017, 6, 863.	0.8	8
479	COPD Course and Comorbidities: Are There Gender Differences?. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1113, 43-51.	0.8	20
480	Pharmacological treatment of COPD: the devil is always in the detail. <i>European Respiratory Journal</i> , 2018, 51, 1800263.	3.1	16
481	Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2018, 2018, CD006897.	1.5	31
482	Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. <i>Respiratory Medicine</i> , 2018, 136, 8-14.	1.3	26
483	Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. <i>European Respiratory Review</i> , 2018, 27, 170113.	3.0	133
484	Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. <i>Thorax</i> , 2018, 73, 422-430.	2.7	201
485	Predictors of short-term LAMA ineffectiveness in treatment naïve patients with moderate to severe COPD. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 247-258.	1.0	2
486	Comparison of respiratory system impedance in asthma and COPD: A prospective observational study. <i>Respirology</i> , 2018, 23, 478-484.	1.3	10
487	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , 2018, 51, 1702146.	3.1	60
488	Pulmonary quantitative CT imaging in focal and diffuse disease: current research and clinical applications. <i>British Journal of Radiology</i> , 2018, 91, 20170644.	1.0	36
489	The Complexity of a Respiratory Patient. , 2018, , 37-43.		0
490	Guías de práctica clínica o medicina personalizada en la enfermedad pulmonar obstructiva crónica. <i>Archivos De Bronconeumología</i> , 2018, 54, 247-248.	0.4	3
491	COPD and Bronchiectasis. , 2018, , 107-127.		1

#	ARTICLE	IF	CITATIONS
492	Clinical Practice Guidelines or Personalized Medicine in Chronic Obstructive Pulmonary Disease?. Archivos De Bronconeumologia, 2018, 54, 247-248.	0.4	1
493	High Imminent Vertebral Fracture Risk in Subjects With COPD With a Prevalent or Incident Vertebral Fracture. Journal of Bone and Mineral Research, 2018, 33, 1233-1241.	3.1	18
495	Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 108-117.	0.7	11
496	Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 739-750.	2.5	53
497	Daily Symptom Variability in Patients With Stable COPD: A Narrative Review. Western Journal of Nursing Research, 2018, 40, 1543-1561.	0.6	6
498	On the Potential Role of MRI Biomarkers of COPD to Guide Bronchoscopic Lung Volume Reduction. Academic Radiology, 2018, 25, 159-168.	1.3	8
499	The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study. Respirology, 2018, 23, 485-491.	1.3	9
500	Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2018, 12, 103-112.	1.0	1
501	The revised GOLD 2017 COPD categorization in relation to comorbidities. Respiratory Medicine, 2018, 134, 79-85.	1.3	45
502	Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 21-26.	0.7	66
503	GOLD stage predicts thoracic aortic calcifications in patients with COPD. Experimental and Therapeutic Medicine, 2019, 17, 967-973.	0.8	2
504	Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. International Journal of COPD, 2018, Volume 13, 3947-3955.	0.9	29
505	Once-daily long-acting beta ₂ -agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. The Cochrane Library, 2018, 8, CD012355.	1.5	6
506	Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease. Scientific Reports, 2018, 8, 16559.	1.6	17
507	Ectopic adiposity and cardiometabolic health in COPD. International Journal of COPD, 2018, Volume 13, 3331-3340.	0.9	16
508	Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory Research, 2018, 19, 224.	1.4	6
509	Long-term outcomes following first short-term clinically important deterioration in COPD. Respiratory Research, 2018, 19, 222.	1.4	21
510	Old Friends, Old Wine, and Old COPD Classification Are Best. Tuberculosis and Respiratory Diseases, 2018, 81, 347.	0.7	2

#	ARTICLE	IF	CITATIONS
511	Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3983-3995.	0.9	12
512	Clinical impacts of the classification by 2017 GOLD guideline comparing previous ones on outcomes of COPD in real-world cohorts. <i>International Journal of COPD</i> , 2018, Volume 13, 3473-3484.	0.9	12
513	The Comparison of Clinical Variables in Two Classifications: GOLD 2017 Combined Assessment and Spirometric Stage of Chronic Obstructive Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 281.	0.7	3
514	The role of CAT in evaluating the response to treatment of patients with AECOPD. <i>International Journal of COPD</i> , 2018, Volume 13, 2849-2858.	0.9	19
515	Right heart failure as a risk factor for severe exacerbation in patients with chronic obstructive pulmonary disease: Prospective cohort study. <i>Clinical Respiratory Journal</i> , 2018, 12, 2635-2641.	0.6	6
516	Biomarkers in COPD – Challenging, Real or Illusive. <i>Folia Medica</i> , 2018, 60, 351-363.	0.2	2
517	Non-pharmacological interventions for breathlessness in people with cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , 0, , 1-15.	0.6	7
519	Quantitative computed tomography phenotypes, spirometric parameters, and episodes of exacerbation in heavy smokers: An analysis from South America. <i>PLoS ONE</i> , 2018, 13, e0205273.	1.1	4
521	Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. <i>Respiratory Medicine</i> , 2018, 145, 130-137.	1.3	5
522	Dyspnea and the Varying Pathophysiologic Manifestations of Chronic Obstructive Pulmonary Disease Evaluated by Cardiopulmonary Exercise Testing With Arterial Blood Analysis. <i>Frontiers in Physiology</i> , 2018, 9, 1293.	1.3	7
523	Different Pattern of Chronic Obstructive Pulmonary Disease Assessment Test Score between Chronic Bronchitis and Non-chronic Bronchitis Patients. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 228.	0.7	7
524	Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT). <i>International Journal of COPD</i> , 2018, Volume 13, 1701-1711.	0.9	1
525	Chronic cough as a novel phenotype of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018, Volume 13, 1793-1801.	0.9	25
526	The respiratory physiome: Clustering based on a comprehensive lung function assessment in patients with COPD. <i>PLoS ONE</i> , 2018, 13, e0201593.	1.1	30
527	Impact of using the new GOLD classification on the distribution of COPD severity in clinical practice. <i>International Journal of COPD</i> , 2018, Volume 13, 351-356.	0.9	9
528	Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 18.	1.1	8
529	The COPDnet integrated care model. <i>International Journal of COPD</i> , 2018, Volume 13, 2225-2235.	0.9	18
530	Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. <i>International Journal of COPD</i> , 2018, Volume 13, 499-508.	0.9	3

#	ARTICLE	IF	CITATIONS
531	The features of AECOPD with carbon dioxide retention. BMC Pulmonary Medicine, 2018, 18, 124.	0.8	7
532	Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients. International Journal of COPD, 2018, Volume 13, 761-769.	0.9	12
533	Tailoring Treatment in Obstructive Lung Disease: Asthma, COPD, Asthma/COPD Overlap and Eosinophilic COPD. Current Geriatrics Reports, 2018, 7, 181-189.	1.1	0
534	Nitrogen single-breath washout test for evaluating exercise tolerance and quality of life in patients with chronic obstructive pulmonary disease. Brazilian Journal of Medical and Biological Research, 2018, 51, e7059.	0.7	4
535	The triad of obstructive sleep apnea syndrome, COPD, and obesity: sensitivity of sleep scales and respiratory questionnaires. Jornal Brasileiro De Pneumologia, 2018, 44, 202-206.	0.4	11
536	Evaluation of the COPDnet integrated care model in patients with COPD: the study protocol. International Journal of COPD, 2018, Volume 13, 2237-2244.	0.9	5
537	High risk of subclinical atherosclerosis in COPD exacerbator phenotype. Respiratory Medicine, 2018, 141, 165-171.	1.3	8
538	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. European Respiratory Journal, 2018, 52, 1800328.	3.1	138
539	Surfactant Protein D in Respiratory and Non-Respiratory Diseases. Frontiers in Medicine, 2018, 5, 18.	1.2	165
540	Changes in the Burden of Comorbidities in Patients with COPD and Asthma—COPD Overlap According to the GOLD 2017 Recommendations. Lung, 2018, 196, 591-599.	1.4	13
541	Design and application of an MR reference phantom for multicentre lung imaging trials. PLoS ONE, 2018, 13, e0199148.	1.1	11
542	Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD. Jornal Brasileiro De Pneumologia, 2018, 44, 36-41.	0.4	8
543	Coexistence of Chronic Bronchitis in Chronic Obstructive Lung Disease. Advances in Experimental Medicine and Biology, 2018, 1114, 1-9.	0.8	3
544	Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation, 2018, 16, 17.	0.6	4
545	Co-existence of COPD and bronchiectasis: a risk factor for a high ratio of main pulmonary artery to aorta diameter (PA:A) from computed tomography in COPD patients. International Journal of COPD, 2018, Volume 13, 675-681.	0.9	10
546	High prevalence of bronchiectasis in emphysema-predominant COPD patients. International Journal of COPD, 2018, Volume 13, 2041-2047.	0.9	20
547	The physical, mental, and social impact of COPD in a population-based sample: results from the Longitudinal Aging Study Amsterdam. Npj Primary Care Respiratory Medicine, 2018, 28, 30.	1.1	28
548	Neurocognitive Impairment as Systemic Effects of COPD. , 0, , .		3

#	ARTICLE	IF	CITATIONS
549	Alternative definitions of chronic bronchitis and their correlation with CT parameters. International Journal of COPD, 2018, Volume 13, 1893-1899.	0.9	11
550	Symptom-related sputum microbiota in stable chronic obstructive pulmonary disease. International Journal of COPD, 2018, Volume 13, 2289-2299.	0.9	16
552	COPD stands for complex obstructive pulmonary disease. European Respiratory Review, 2018, 27, 180027.	3.0	32
553	Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Respiratory Medicine, 2018, 141, 14-19.	1.3	12
554	COPD beyond proximal bronchial obstruction: phenotyping and related tools at the bedside. European Respiratory Review, 2019, 28, 190010.	3.0	13
555	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). Respiratory Research, 2019, 20, 153.	1.4	25
556	The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661986005.	1.0	22
557	<p><p>Personalized medicine for patients with COPD: where are we?<p>. International Journal of COPD, 2019, Volume 14, 1465-1484.	0.9	55
558	Patient assessment and selection for pulmonary rehabilitation. Respirology, 2019, 24, 844-853.	1.3	18
559	A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Advances in Therapy, 2019, 36, 2434-2449.	1.3	22
560	<p>Contributions of cardiovascular risk and smoking to chronic obstructive pulmonary disease (COPD)-related changes in brain structure and function</p>. International Journal of COPD, 2019, Volume 14, 1855-1866.	0.9	16
561	<p>External Validation Of The Updated ADO Score In COPD Patients From The Birmingham COPD Cohort</p>. International Journal of COPD, 2019, Volume 14, 2395-2407.	0.9	6
562	Digital interventions for the management of chronic obstructive pulmonary disease. The Cochrane Library, 0, , .	1.5	7
564	EARLY COPD: determinantes de la aparición y progresión de la enfermedad pulmonar obstructiva crónica en adultos jóvenes. Protocolo de un estudio caso-control con seguimiento. Archivos De Bronconeumología, 2019, 55, 312-318.	0.4	8
565	Diffusing Capacity of Carbon Monoxide in Assessment of COPD. Chest, 2019, 156, 1111-1119.	0.4	58
566	Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC. Respiratory Medicine, 2019, 156, 58-68.	1.3	40
567	Pneumoproteins are associated with pulmonary function in HIV-infected persons. PLoS ONE, 2019, 14, e0223263.	1.1	8
568	Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2019, 381, 1248-1256.	13.9	324

#	ARTICLE	IF	CITATIONS
569	Disruption of white matter connectivity in chronic obstructive pulmonary disease. PLoS ONE, 2019, 14, e0223297.	1.1	1
570	Monitoring peak expiratory flow could predict COPD exacerbations: A prospective observational study. Respiratory Medicine, 2019, 148, 43-48.	1.3	5
571	Thoracic Kyphosis on Chest CT Scans Is Associated With Incident Vertebral Fractures in Smokers. Journal of Bone and Mineral Research, 2019, 34, 859-866.	3.1	3
572	Predictive and modifying factors of bone mineral density decline in patients with COPD. Respiratory Medicine, 2019, 148, 13-23.	1.3	5
573	Prediction of Treatment Response in Patients with Chronic Obstructive Pulmonary Disease by Determination of Airway Dimensions with Baseline Computed Tomography. Korean Journal of Radiology, 2019, 20, 304.	1.5	8
574	<p><p>Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study</p><p>International Journal of COPD, 2019, Volume 14, 939-951.	0.9	5
575	Hypermethylation of mitochondrial transcription factor A induced by cigarette smoke is associated with chronic obstructive pulmonary disease. Experimental Lung Research, 2019, 45, 101-111.	0.5	10
576	<p><p>New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation</p><p>International Journal of COPD, 2019, Volume 14, 1119-1125.	0.9	14
577	Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A CaseâControl Study With Follow-Up. Archivos De Bronconeumologia, 2019, 55, 312-318.	0.4	4
578	COPD: To Be or Not to Be, That is the Question. American Journal of Medicine, 2019, 132, 1271-1278.	0.6	10
579	Aortic Pulse Wave Velocity as a Measure of Cardiovascular Risk in Chronic Obstructive Pulmonary Disease: Two-Year Follow-Up Data from the ARCADE Study. Medicina (Lithuania), 2019, 55, 89.	0.8	7
580	Vertebral bone attenuation in Hounsfield Units and prevalent vertebral fractures are associated with the short-term risk of vertebral fractures in current and ex-smokers with and without COPD: a 3-year chest CT follow-up study. Osteoporosis International, 2019, 30, 1561-1571.	1.3	10
581	Classification and treatment of chronic obstructive pulmonary disease outpatients in China according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: comparison with GOLD 2014. Journal of Thoracic Disease, 2019, 11, 1303-1315.	0.6	21
582	<p><p>Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study</p><p>International Journal of COPD, 2019, Volume 14, 995-1008.	0.9	33
583	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respiratory Research, 2019, 6, e000431.	1.2	26
584	Influence of Anxiety/Depression on the Subjective Evaluation of Cough in Patients with Chronic Obstructive Pulmonary Disease and Obesity. Medicina (Lithuania), 2019, 55, 134.	0.8	4
586	Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. Respiratory Research, 2019, 20, 63.	1.4	23
587	Prediction of Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Quantitative CT Parameters. Korean Journal of Radiology, 2019, 20, 683.	1.5	29

#	ARTICLE	IF	CITATIONS
588	<p>Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study</p>. International Journal of COPD, 2019, Volume 14, 565-573.	0.9	25
589	Women and COPD: do we need more evidence?. European Respiratory Review, 2019, 28, 180055.	3.0	85
590	<p>Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths</p>. International Journal of COPD, 2019, Volume 14, 331-341.	0.9	17
591	High Prevalence of Diabetes Mellitus in a Cohort of Patients with Chronic Obstructive Pulmonary Disease in Trinidad, West Indies. Turkish Thoracic Journal, 2019, 20, 12-17.	0.2	10
592	Feasibility of neoadjuvant therapy for elderly patients with locally advanced rectal cancer. Surgery Today, 2019, 49, 694-703.	0.7	4
593	Palliative Care in Chronic Obstructive Pulmonary Disease. Medical Clinics of North America, 2019, 103, 517-526.	1.1	5
594	How different are COPD-specific patient reported outcomes, health status, dyspnoea and respiratory symptoms? An observational study in a working population. BMJ Open, 2019, 9, e025132.	0.8	7
595	Chronic obstructive pulmonary disease at the beginning of the XXI Century. Journal of Thoracic Disease, 2019, 11, E210-E213.	0.6	1
596	Exhaled Nitric Oxide in COPD. Current Respiratory Medicine Reviews, 2019, 15, 71-78.	0.1	4
598	COPD and Comorbidities: Relating Mechanisms and Treatment. Current Respiratory Medicine Reviews, 2019, 15, 90-101.	0.1	1
599	<p>Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial</p>. International Journal of COPD, 2019, Volume 14, 2681-2695.	0.9	24
600	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661988812.	1.0	12
601	Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study. Npj Primary Care Respiratory Medicine, 2019, 29, 45.	1.1	38
602	<p>Mixed Phenotype of Emphysema and Airway Wall Thickening Is Associated with Frequent Exacerbation in Chronic Obstructive Pulmonary Disease Patients</p>. International Journal of COPD, 2019, Volume 14, 3035-3042.	0.9	12
603	The roles of microRNAs in the pathogenesis of chronic obstructive pulmonary disease. International Immunopharmacology, 2019, 67, 335-347.	1.7	37
604	Comprehensive Lung Function Assessment Does not Allow to Infer Response to Pulmonary Rehabilitation in Patients with COPD. Journal of Clinical Medicine, 2019, 8, 27.	1.0	18
605	Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia. Chronic Respiratory Disease, 2019, 16, 147997231880948.	1.0	29
606	Machine Learning Algorithms Utilizing Functional Respiratory Imaging May Predict COPD Exacerbations. Academic Radiology, 2019, 26, 1191-1199.	1.3	20

#	ARTICLE	IF	CITATIONS
607	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. <i>Respiratory Research</i> , 2019, 20, 4.	1.4	15
608	Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 724-730.	1.1	3
609	Muscle wasting in the presence of disease, why is it so variable?. <i>Biological Reviews</i> , 2019, 94, 1038-1055.	4.7	7
610	Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study. <i>Respiratory Medicine</i> , 2019, 146, 1-9.	1.3	22
611	Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?. <i>European Journal of Pharmacology</i> , 2019, 842, 99-110.	1.7	48
612	Diagnosis of Asthma and Chronic Obstructive Pulmonary Disease. , 2019, , 171-184.		0
613	Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance. <i>Journal of Innate Immunity</i> , 2020, 12, 203-225.	1.8	57
614	Physiological and perceptual responses to exercise according to locus of symptom limitation in COPD. <i>Respiratory Physiology and Neurobiology</i> , 2020, 273, 103322.	0.7	3
615	Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice. <i>Advances in Therapy</i> , 2020, 37, 17-26.	1.3	15
616	When Harry Met Sally, or When Machine Learning Met Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 263-265.	2.5	4
617	Association between vertebral fractures and coronary artery calcification in current and former smokers in the ECLIPSE cohort. <i>Osteoporosis International</i> , 2020, 31, 297-305.	1.3	3
618	Phenotyping COPD. , 2020, , 369-379.		0
619	Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. <i>Respiratory Medicine</i> , 2020, 172, 106117.	1.3	4
620	<p>Risk Factors for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Industrial Regions of China: A Multicenter Cross-Sectional Study</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2249-2256.	0.9	13
621	COPD 2020: changes and challenges. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L879-L883.	1.3	66
622	Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 405-419.	0.8	38
623	Assessing Symptom Burden. <i>Clinics in Chest Medicine</i> , 2020, 41, 367-373.	0.8	4
624	Is group C really needed as a separate group from D in COPD? A single-center cross-sectional study. <i>Pulmonology</i> , 2023, 29, 188-193.	1.0	2

#	ARTICLE	IF	CITATIONS
625	Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study. <i>Journal of Thoracic Disease</i> , 2020, 12, 4253-4261.	0.6	14
626	Bringing COPD control into the consultation. <i>Respirology</i> , 2020, 25, 1110-1111.	1.3	0
627	Metabolic profiling shows pre-existing mitochondrial dysfunction contributes to muscle loss in a model of ICU-acquired weakness. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1321-1335.	2.9	22
628	A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2020, 20, 193.	0.8	15
629	Patología respiratoria en la era del big data. <i>Open Respiratory Archives</i> , 2020, 2, 284-288.	0.0	0
630	Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662091699.	1.0	5
631	COPD phenotypes and machine learning cluster analysis: A systematic review and future research agenda. <i>Respiratory Medicine</i> , 2020, 171, 106093.	1.3	19
632	Sex differences between women and men with COPD: A new analysis of the 3CIA study. <i>Respiratory Medicine</i> , 2020, 171, 106105.	1.3	50
633	<p>Clinical Characteristics of Chronic Obstructive Pulmonary Disease in Female Patients: Findings from a KOCOSS Cohort</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2217-2224.	0.9	9
634	Integrating Comorbidities and Phenotype-Based Medicine in Patient-Centered Medicine in COPD. <i>Journal of Clinical Medicine</i> , 2020, 9, 2745.	1.0	3
635	Lung cancer and obstructive lung disease in never smokers. <i>Journal of Thoracic Disease</i> , 2020, 12, 3934-3939.	0.6	0
636	Heart Failure is Highly Prevalent and Difficult to Diagnose in Severe Exacerbations of COPD Presenting to the Emergency Department. <i>Journal of Clinical Medicine</i> , 2020, 9, 2644.	1.0	9
637	Correlation of Arterial CO2 and Respiratory Impedance Values among Subjects with COPD. <i>Journal of Clinical Medicine</i> , 2020, 9, 2819.	1.0	1
638	Association between patient-reported outcomes and exercise test outcomes in patients with COPD before and after pulmonary rehabilitation. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 300.	1.0	8
639	Twenty years of changes in the disease assessment method of the Global Initiative for Chronic Obstructive Lung Disease. <i>Chinese Medical Journal</i> , 2020, 133, 2098-2103.	0.9	1
640	Obstructive Sleep Apnea Increases the Prevalence of Hypertension in Patients with Chronic Obstructive Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 523-532.	0.7	11
641	Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status. <i>JAMA Internal Medicine</i> , 2020, 180, 1306.	2.6	74
642	Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme. <i>Genetic Epidemiology</i> , 2020, 44, 748-758.	0.6	7

#	ARTICLE	IF	CITATIONS
643	Impact of tobacco-related chronic obstructive pulmonary disease on developmental trajectories of comorbidities in the Taiwan population. <i>Scientific Reports</i> , 2020, 10, 21025.	1.6	3
644	Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1488-1502.	2.5	107
645	Active screening for COPD among hospitalized smokers – a feasibility study. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 2040622320971111.	1.1	3
646	<p>Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2467-2476.	0.9	11
647	<p>Influence of Comorbidities on the Survival of COPD Patients According to Phenotypes</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2759-2767.	0.9	1
648	Effects of toner-handling work on respiratory function, chest X-ray findings, and biomarkers of inflammation, allergy, and oxidative stress: a 10-year prospective Japanese cohort study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 280.	0.8	1
649	<p>Different Clusters in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Two-Center Study in Brazil</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2847-2856.	0.9	2
650	Challenges to the Application of Integrated, Personalized Care for Patients with COPD – A Vision for the Role of Clinical Information. <i>Journal of Clinical Medicine</i> , 2020, 9, 1311.	1.0	9
651	Interventions to Improve the Quality of Life of Patients with Chronic Obstructive Pulmonary Disease: A Global Mapping During 1990 – 2018. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3089.	1.2	14
652	Measuring disease activity in COPD: is clinically important deterioration the answer?. <i>Respiratory Research</i> , 2020, 21, 134.	1.4	18
653	Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 176.	0.8	1
654	The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1013-1021.	5.2	72
655	Goals of COPD treatment: Focus on symptoms and exacerbations. <i>Respiratory Medicine</i> , 2020, 166, 105938.	1.3	135
656	Calling Time on Spirometry: Unlocking the Silent Zone in Acute Rejection after Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1468-1470.	2.5	9
657	<p>Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 543-552.	0.9	15
658	Inspiratory Muscle Training in COPD. <i>Respiratory Care</i> , 2020, 65, 1189-1201.	0.8	30
659	Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD. <i>Chest</i> , 2020, 158, 722-734.	0.4	24
660	<p>Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1529-1543.	0.9	7

#	ARTICLE	IF	CITATIONS
661	KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea. <i>BMJ Open</i> , 2020, 10, e034090.	0.8	19
662	Association Between Inflammatory Pathways and Phenotypes of Pulmonary Dysfunction Using Cluster Analysis in Persons Living With HIV and HIV-Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 189-196.	0.9	12
663	Analysis of high-resolution computed tomography phenotypes and pulmonary function in chronic obstructive pulmonary disease. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988945.	0.4	0
664	<p>Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 3053-3061.	0.9	2
665	Comparative analysis of pathophysiological parameters between emphysematous smokers and emphysematous patients with COPD. <i>Scientific Reports</i> , 2020, 10, 420.	1.6	9
666	Rebuttal From Drs Mannino and Thomashow. <i>Chest</i> , 2020, 157, 14-15.	0.4	0
667	The validity and reliability of four-meter gait speed test for stable interstitial lung disease patients: the prospective study. <i>Journal of Thoracic Disease</i> , 2020, 12, 1296-1304.	0.6	8
668	Long-Term Mortality and Medical Burden of Patients with Chronic Obstructive Pulmonary Disease with and without Subsequent Stroke Episodes. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2550.	1.2	3
669	DCT-MIL: Deep CNN transferred multiple instance learning for COPD identification using CT images. <i>Physics in Medicine and Biology</i> , 2020, 65, 145011.	1.6	21
670	Predictive value of control of <scp>COPD</scp> for risk of exacerbations: An international, prospective study. <i>Respirology</i> , 2020, 25, 1136-1143.	1.3	24
671	<p>Chronic Obstructive Pulmonary Disease in Women: A Biologically Focused Review with a Systematic Search Strategy</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 711-721.	0.9	17
672	Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2020, 17, 829-838.	1.5	17
673	Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort. <i>Respiratory Research</i> , 2020, 21, 77.	1.4	44
674	Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 389-400.	1.0	18
675	A perspective for chronic obstructive pulmonary disease (COPD) management: six key clinical questions to improve disease treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 427-437.	0.9	5
676	The airway microbiome in COPD, bronchiectasis and bronchiectasisâ€COPD overlap. <i>Clinical Respiratory Journal</i> , 2021, 15, 123-133.	0.6	35
678	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. <i>ERJ Open Research</i> , 2021, 7, 00663-2020.	1.1	7
679	Artificial Intelligence and Machine Learning in Chronic Airway Diseases: Focus on Asthma and Chronic Obstructive Pulmonary Disease. <i>International Journal of Medical Sciences</i> , 2021, 18, 2871-2889.	1.1	41

#	ARTICLE	IF	CITATIONS
680	Sex Differences in Chronic Obstructive Pulmonary Disease. <i>Physiology in Health and Disease</i> , 2021, , 169-195.	0.2	1
681	Digital Health for Enhanced Understanding and Management of Chronic Conditions: COPD as a Use Case. , 2021, , 256-273.		0
682	Einbeziehung von Komorbiditaten und phanotypbasierter Medizin beim patientenzentrierten COPD-Management. <i>Karger Kompass Pneumologie</i> , 2021, , 60-67.	0.0	0
683	Gastrointestinal Manifestations of Non-GI Disorders. , 2021, , 2117-2166.		0
684	Functional neurological disorder: lighting the way to a new paradigm for medicine. <i>Brain</i> , 2021, 144, 3279-3282.	3.7	9
685	Dyspnoea and symptom burden in mild-to-moderate COPD: the Canadian Cohort Obstructive Lung Disease Study. <i>ERJ Open Research</i> , 2021, 7, 00960-2020.	1.1	7
686	A Double-blind Randomized Controlled Trial on the Effects of Montelukast on the Serum Level of Inflammatory Factors in Patients with Chronic Obstructive Pulmonary Disease. <i>Shiraz E Medical Journal</i> , 2021, 22, .	0.1	0
687	Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort. <i>International Journal of COPD</i> , 2021, Volume 16, 225-244.	0.9	5
688	Clinical phenotypes of chronic obstructive pulmonary disease in patients treated at the Hospital Neumolgico de La Habana.. <i>International Journal of Medical and Surgical Sciences</i> , 0, , 1-12.	0.0	0
689	Small Airways Disease, Biomarkers and COPD: Where are We?. <i>International Journal of COPD</i> , 2021, Volume 16, 351-365.	0.9	14
690	Associations between bone attenuation and prevalent vertebral fractures on chest CT scans differ with vertebral fracture locations. <i>Osteoporosis International</i> , 2021, 32, 1869-1877.	1.3	4
691	The autoreactivity phenomenon in the pathogenesis of asthma-COPD overlap (ACO). <i>Pulmonologiya</i> , 2021, 31, 46-56.	0.2	0
692	Assessment of Ventilatory Heterogeneity in Chronic Obstructive Pulmonary Disease Using the Inspired Sinewave Test. <i>International Journal of COPD</i> , 2021, Volume 16, 401-413.	0.9	2
693	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021, 58, 2003927.	3.1	43
694	Comorbidities and mortality risk factors for patients with bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 623-634.	1.0	9
695	Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study. <i>European Respiratory Journal</i> , 2021, 58, 2003823.	3.1	22
696	Underestimation of respiratory symptoms by smokers: a thorn in chronic obstructive pulmonary disease diagnosis. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 14.	1.1	5
697	Clinical heterogeneity of a population of patients admitted to the Emergency Department with a diagnosis of COPD-exacerbation: Relevance of cardiovascular comorbidities. <i>Emergency Care Journal</i> , 2021, 17, .	0.2	0

#	ARTICLE	IF	CITATIONS
698	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. <i>Scientific Reports</i> , 2021, 11, 4916.	1.6	12
699	Association Between Airflow Limitation and Carotid Intima-Media Thickness in the Japanese Population. <i>International Journal of COPD</i> , 2021, Volume 16, 715-726.	0.9	1
700	Comorbid conditions at chronic obstructive pulmonary disease: the questions under investigation and discussion. <i>Ukrainian Therapeutical Journal</i> , 2021, , .	0.0	0
701	Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. <i>International Journal of COPD</i> , 2021, Volume 16, 945-955.	0.9	1
702	Digital interventions for the management of chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2021, 2021, CD013246.	1.5	31
703	Structural and functional changes in <sc>COPD</sc>: What we have learned from imaging. <i>Respirology</i> , 2021, 26, 731-741.	1.3	4
704	CT, MRI, COPD, and Worsening FEV1; “Once You Do Know What the Question Actually Is, You'll Know What the Answer Means” <i>Academic Radiology</i> , 2021, 28, 507-508.	1.3	0
706	Muscle mass and function are related to respiratory function in chronic obstructive pulmonary disease. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 34.	0.9	3
707	Efficacy of domiciliary noninvasive ventilation on clinical outcomes in posthospital chronic obstructive pulmonary disease patients: a meta-analysis of randomized controlled trials. <i>Annals of Palliative Medicine</i> , 2021, 10, 5137-5145.	0.5	3
708	Imbalance Between Injury and Defense in the COPD Emphysematous Phenotype. <i>Frontiers in Medicine</i> , 2021, 8, 653332.	1.2	1
709	Identification of Mucus-Associated Molecular Subtypes of Chronic Obstructive Pulmonary Disease: A Latent Profile Analysis Based on MUC5B-Associated Genes. <i>Medical Science Monitor</i> , 2021, 27, e931222.	0.5	2
710	One-year clinically important deterioration and long-term clinical course in Japanese patients with COPD: a multicenter observational cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 159.	0.8	4
711	Abnormal pulmonary flow is associated with impaired right ventricular coupling in patients with COPD. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3039-3048.	0.7	5
712	Longitudinal changes in total and regional body composition in patients with chronic obstructive pulmonary disease. <i>Respirology</i> , 2021, 26, 851-860.	1.3	8
713	Clinico demographic profile of patients with bronchiectasis “ A cross sectional study. <i>IP Indian Journal of Immunology and Respiratory Medicine</i> , 2021, 6, 111-116.	0.1	0
714	Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study. <i>ERJ Open Research</i> , 2021, 7, 00020-2021.	1.1	11
715	Testosterone deficiency promotes the development of pulmonary emphysema in orchietomized mice exposed to elastase. <i>Biochemical and Biophysical Research Communications</i> , 2021, 558, 94-101.	1.0	5
716	Complexity of design in early phase respiratory clinical trials; evaluating impact of primary endpoints and sponsor size. <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100793.	0.5	0

#	ARTICLE	IF	CITATIONS
717	COPD and preclinical cardiovascular disease. <i>Årno-Rossijskij Årurnal TerapevtiÅeskoj Praktiki</i> , 2021, 2, 70-79.	0.1	0
718	Sputum Protein Biomarkers in Airway Diseases: A Pilot Study. <i>International Journal of COPD</i> , 2021, Volume 16, 2203-2215.	0.9	12
719	The "Slow Horse Racing Effect" on Lung Function in Adult Life in Chronic Obstructive Pulmonary Disease Associated to Biomass Exposure. <i>Frontiers in Medicine</i> , 2021, 8, 700836.	1.2	9
720	Seven Pillars of Small Airways Disease in Asthma and COPD. <i>Chest</i> , 2021, 160, 114-134.	0.4	22
721	A genome-wide association study of quantitative computed tomographic emphysema in Korean populations. <i>Scientific Reports</i> , 2021, 11, 16692.	1.6	2
722	Comparative Impact of Depressive Symptoms and FEV ₁ % on Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 171-178.	1.5	7
723	Multidimensional indices in the assessment of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2021, 185, 106519.	1.3	12
724	Resting Breathing Instability During Wakefulness as a Predictor of Clinical Outcome in COPD. <i>Respiratory Care</i> , 2021, 66, 1477-1484.	0.8	0
725	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021, Volume 16, 2301-2322.	0.9	9
726	The correlation between quadriceps muscle strength and endurance and exercise performance in patients with COPD. <i>Journal of Applied Physiology</i> , 2021, 131, 589-600.	1.2	5
727	Which LABA/LAMA should be chosen in COPD patients in real life?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 71, 102076.	1.1	3
728	Adherence to Inhaled Therapy in Patients with COPD Associated to Pneumoconiosis. <i>International Journal of COPD</i> , 2021, Volume 16, 2697-2706.	0.9	3
729	Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease. <i>Respiratory Medicine</i> , 2021, 186, 106529.	1.3	0
730	The cardiovascular phenotype of Chronic Obstructive Pulmonary Disease (COPD): Applying machine learning to the prediction of cardiovascular comorbidities. <i>Respiratory Medicine</i> , 2021, 186, 106528.	1.3	6
731	Differences Between Men and Women with Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2021, 42, 443-456.	0.8	8
732	Integrated disease management interventions for patients with chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2021, 2021, CD009437.	1.5	24
733	Nanotechnology based advanced therapeutic strategies for targeting interleukins in chronic respiratory diseases. <i>Chemico-Biological Interactions</i> , 2021, 348, 109637.	1.7	14
734	Comorbidities in Patients With Chronic Obstructive Pulmonary Disease. , 2022, , 663-674.		0

#	ARTICLE	IF	CITATIONS
735	An Introduction to Advanced Lung Disease. <i>Respiratory Medicine</i> , 2021, , 11-25.	0.1	0
736	Validation of Clinical Characteristics and Effectiveness of Pulmonary Rehabilitation in a COPD Population with Discrepancy between Exercise Tolerance and FEV1. <i>Healthcare (Switzerland)</i> , 2021, 9, 53.	1.0	3
737	Surfactant Protein D in Respiratory and Non-Respiratory Diseases. <i>Frontiers in Medicine</i> , 0, 5, .	1.2	1
738	From Systems Understanding to Personalized Medicine: Lessons and Recommendations Based on a Multidisciplinary and Translational Analysis of COPD. <i>Methods in Molecular Biology</i> , 2016, 1386, 283-303.	0.4	10
739	Cardiovascular Comorbidity in Chronic Lung Disease: Gender Differences. <i>Respiratory Medicine</i> , 2020, , 25-43.	0.1	1
741	Protocol for a Single-Blind, Randomized, Parallel-Group Study of a Nonpharmacological Integrated Care Intervention to Reduce the Impact of Breathlessness in Patients with Chronic Obstructive Pulmonary Disease. <i>Palliative Medicine Reports</i> , 2020, 1, 296-306.	0.4	3
742	Occupational exposures and incidence of chronic bronchitis and related symptoms over two decades: the European Community Respiratory Health Survey. <i>Occupational and Environmental Medicine</i> , 2019, 76, oemed-2018-105274.	1.3	17
743	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2001339.	3.1	26
744	Differential diagnosis and impact of cardiovascular comorbidities and pulmonary embolism during COPD exacerbations. , 0, , 114-128.		1
745	Phenotypes and endotypes. , 0, , 133-152.		1
746	The overlap with bronchiectasis. , 0, , 96-108.		2
747	The challenge of palliative care. , 0, , 297-322.		1
749	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. <i>PLoS ONE</i> , 2012, 7, e37483.	1.1	633
750	Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study. <i>PLoS ONE</i> , 2012, 7, e42156.	1.1	95
751	Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality. <i>PLoS ONE</i> , 2012, 7, e51048.	1.1	104
752	Primary Care COPD Patients Compared with Large Pharmaceutically-Sponsored COPD Studies: An UNLOCK Validation Study. <i>PLoS ONE</i> , 2014, 9, e90145.	1.1	77
753	Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0143793.	1.1	18
754	Functional and Prognostic Implications of the Main Pulmonary Artery Diameter to Aorta Diameter Ratio from Chest Computed Tomography in Korean COPD Patients. <i>PLoS ONE</i> , 2016, 11, e0154584.	1.1	14

#	ARTICLE	IF	CITATIONS
755	Chronic Obstructive Pulmonary Disease Subtypes. Transitions over Time. PLoS ONE, 2016, 11, e0161710.	1.1	13
756	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0166745.	1.1	63
757	Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2017, 12, e0172437.	1.1	45
758	Influence of the Lung Microbiota Dysbiosis in Chronic Obstructive Pulmonary Disease Exacerbations: The Controversial Use of Corticosteroid and Antibiotic Treatments and the Role of Eosinophils as a Disease Marker. Journal of Clinical Medicine Research, 2019, 11, 667-675.	0.6	24
759	The Association Between Dietary Intake and Phenotypical Characteristics of COPD in the ECLIPSE Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 115-124.	0.5	9
760	Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 204-213.	0.5	9
761	Health Status of Patients with Chronic Obstructive Pulmonary Disease by Symptom Level. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 643-652.	0.5	9
762	Revealing Methodological Challenges in Chronic Obstructive Pulmonary Disease Studies Assessing Comorbidities: A Narrative Review. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 166-177.	0.5	9
763	Factors associated with bronchiectasis in Korea: a national database study. Annals of Translational Medicine, 2020, 8, 1350-1350.	0.7	17
764	Chronic bronchitis is associated with severe exacerbation and prolonged recovery period in Chinese patients with COPD: a multicenter cross-sectional study. Journal of Thoracic Disease, 2017, 9, 5120-5130.	0.6	10
765	<p>Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate</p>. International Journal of COPD, 2020, Volume 15, 995-1004.	0.9	5
766	<p>Healthcare Service Usage and Costs for Elderly Patients with Obstructive Lung Disease</p>. International Journal of COPD, 2020, Volume 15, 3357-3366.	0.9	4
767	Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. Current Pharmaceutical Design, 2014, 20, 5928-5944.	0.9	63
768	Is Acute Exacerbation of COPD (AECOPD) Related to Viral Infection Associated with Subsequent Mortality or Exacerbation Rate?. Open Respiratory Medicine Journal, 2014, 8, 18-21.	1.3	8
769	Course of COPD Assessment Test (CAT) Scores During Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease Treated in Outpatient Setting. Open Respiratory Medicine Journal, 2015, 9, 39-45.	1.3	2
770	Wearable Finger Pulse Oximetry for Continuous Oxygen Saturation Measurements During Daily Home Routines of Patients With Chronic Obstructive Pulmonary Disease (COPD) Over One Week: Observational Study. JMIR MHealth and UHealth, 2019, 7, e12866.	1.8	70
771	Gender differences in chronic obstructive pulmonary diseases: a narrative review. Panminerva Medica, 2018, 60, 192-199.	0.2	18
772	Comparative analysis of parameters of cardiointervalometry, ergoreflex and data of 6 minute walk test in patients with chronic obstructive pulmonary disease. I P Pavlov Russian Medical Biological Herald, 2019, 27, 49-58.	0.2	3

#	ARTICLE	IF	CITATIONS
773	Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a multidisciplinary opinion document. <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 49-67.	0.5	11
774	Diagnosis and early detection of COPD using spirometry. <i>Journal of Thoracic Disease</i> , 2014, 6, 1557-69.	0.6	92
775	Advanced imaging in COPD: insights into pulmonary pathophysiology. <i>Journal of Thoracic Disease</i> , 2014, 6, 1570-85.	0.6	36
776	Biomarkers of progression of chronic obstructive pulmonary disease (COPD). <i>Journal of Thoracic Disease</i> , 2014, 6, 1532-47.	0.6	111
778	Reducción de la actividad física en pacientes con enfermedad pulmonar obstructiva crónica. <i>Revista Medica De Chile</i> , 2011, 139, 1562-1572.	0.1	11
779	A randomized controlled study on assessment of health status, depression, and anxiety in coal miners with chronic obstructive pulmonary disease following yoga training. <i>International Journal of Yoga</i> , 2016, 9, 137.	0.4	14
780	Cardiovascular comorbidities associated with patients with chronic obstructive pulmonary disease – a hospital-based study. <i>Egyptian Journal of Bronchology</i> , 2019, 13, 591-595.	0.3	4
781	Undiagnosed COPD in Patients with Established Cardiovascular Diseases: Prevalence, Symptoms Profiling and Functional Status. <i>Journal of Pulmonary & Respiratory Medicine</i> , 2011, 01, .	0.1	1
782	Chronic obstructive pulmonary disease – a treatable disease. <i>Swiss Medical Weekly</i> , 2013, 143, w13777.	0.8	18
783	Chronic Obstructive Pulmonary Disease Biomarkers. <i>Eurasian Journal of Pulmonology</i> , 2016, 18, 3-10.	0.2	2
784	Chronic obstructive pulmonary disease in Poland: distribution of patients according to the new GOLD 2011 classification. Cross-sectional survey. <i>Pneumonologia i Alergologia Polska</i> , 2014, 82, 511-517.	0.6	8
785	Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China. <i>Journal of Thoracic Disease</i> , 2021, 13, 5701-5716.	0.6	2
786	Implication of RAGE Polymorphic Variants in COPD Complication and Anti-COPD Therapeutic Potential of sRAGE. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 737-748.	0.7	2
789	Obesity and Chronic Obstructive Pulmonary Disease. , 2013, , 153-164.		0
790	Early chronic obstructive pulmonary disease : Beyond spirometry. <i>World Journal of Respirology</i> , 2013, 3, 57.	0.5	0
791	Endothelial progenitor cells in chronic obstructive pulmonary disease. <i>OA Stem Cells</i> , 2013, 1, .	0.2	0
792	Diagnostic values of biomarkers in acute exacerbation of chronic obstructive pulmonary disease. <i>Pulmonologiya</i> , 2014, , 100-104.	0.2	3
793	Data based Modelling of Expired Airflow Clarifies Chronic Obstructive Pulmonary Disease. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
794	Editorial from Guest Editor (Thematic Issue: Current Approach to COPD Management: Setting a Model) Tj ETQq0 0,0,1rgBT /Oyerlock 10	0.1	0
796	Exploring Expiratory Flow Dynamics to Understand Chronic Obstructive Pulmonary Disease. Communications in Computer and Information Science, 2015, , 233-245.	0.4	0
797	Placing Novel, Fixed-Dose Dual Bronchodilators within the nice Guidelines for Chronic Obstructive Pulmonary Disease -Reflections on the Past, Present and Future. Archives of Pulmonology and Respiratory Care, 0, , 001-008.	0.1	0
798	COPD. Kernboek, 2016, , 47-51.	0.0	0
799	Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 758-768.	0.5	8
800	INDIVIDUALIZED APPROACH, EVIDENCE, PRACTICE (BASED ON PROCEEDINGS OF THE 26TH NATIONAL) Tj ETQq1 1,0,784314 rgBT /Ov	0.2	0
801	PATHOGENIC PARTICULARITIES OF CARDIOVASCULAR CONTINUUM IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Pulmonologiya, 2016, 26, 610-617.	0.2	1
802	Cohort Study in COPD: Introduction to COPD Cohorts (The KOLD and COPDGene Study) and Collaborative Approaches. , 2017, , 313-320.		0
803	PAO2 Mapping Using HP Gas MRI. , 2017, , 149-167.		1
804	Comorbidities: Assessment and Treatment. , 2017, , 267-297.		0
805	Subtyping Chronic Obstructive Pulmonary Disease Using Peripheral Blood Proteomics. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 93-104.	0.5	4
806	Drugs for chronic obstructive pulmonary disease. Australian Prescriber, 2017, 40, 15-19.	0.5	8
807	Updates in computed tomography assessment of emphysema using computed tomography lung analysis. Egyptian Journal of Bronchology, 2017, 11, 104-110.	0.3	2
808	DIAGNOSTICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN REAL CLINICAL PRACTICE: HYPODIAGNOSTICS OR HYPERDIAGNOSTICS. EUREKA Health Sciences, 2017, 3, 65-72.	0.1	0
810	Reply: Lung Function Abnormalities in Smokers with Ischemic Heart Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1537-1538.	2.5	0
811	Cardiorespiratory continuum: general pathogenetic aspects. Klinicheskaia Meditsina, 2017, 95, 875-880.	0.2	0
812	HISTORIC DEVELOPMENT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLASSIFICATION. Tuberculosis and Lung Diseases, 2018, 96, 51-56.	0.2	0
813	Lung, Fat and Bone: Increased Adiponectin Associates with the Combination of Smoking-Related Lung Disease and Osteoporosis. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 134-143.	0.5	3

#	ARTICLE	IF	CITATIONS
814	Clinical and pulmonary functions profiling of patients with chronic obstructive pulmonary disease experiencing frequent acute exacerbations. <i>Lung India</i> , 2018, 35, 21.	0.3	4
815	Characteristics and risk factors for inconsistency between the risk of exacerbations and the severity of airflow limitation in COPD based on GOLD 2017: A retrospective, cross-sectional study. <i>PLoS ONE</i> , 2018, 13, e0193880.	1.1	2
816	COPD and Overweight, as a Problem in Present-Day Pulmonology. <i>Galician Medical Journal</i> , 2018, 25, .	0.1	0
817	Study of the Bronchoreversibility and Outcomes in Patients with Chronic Obstructive Pulmonary Disease (COPD). <i>The Egyptian Journal of Hospital Medicine</i> , 2018, 72, 5688-5694.	0.0	0
818	A relationship between chronic obstructive pulmonary disease, obesity and melatonin level. <i>Pulmonologiya</i> , 2018, 28, 359-367.	0.2	1
821	The Importance of Neutrophil to Lymphocyte Ratio and Peripheral Blood Eosinophilia in Chronic Obstructive Pulmonary Disease Patients with Acute Exacerbation: Recent Studies. <i>Open Journal of Respiratory Diseases</i> , 2019, 09, 37-47.	0.1	0
822	COPD: Neuer GOLD-Standard betont die individualisierte Therapie. <i>Deutsches A&#x0308;rztblatt International</i> , 0, , .	0.6	1
824	CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN WOMEN. <i>Bulletin Physiology and Pathology of Respiration</i> , 2019, , 1-1.	0.0	1
825	Asthma“COPD“Bronchiectasis combination: an unstudied triplet. <i>Pneumologia</i> , 2019, 68, 58-60.	0.1	2
827	Aspects extrapulmonaires des exacerbations de bronchopneumopathie chronique obstructive. <i>Annales Francaises De Medecine D'Urgence</i> , 2020, 10, 139-145.	0.0	0
828	KRONÅk OBSTRÅktäf AKCÅÅzer hastalÅzinda fenotÅplere gÅre kan bÅyobelÅrteÅlerÅnÅn karÅzilÅÅtirilmas Bilimleri Dergisi, 2020, 29, 46-50.	0.1	0
832	The concept of control in chronic obstructive pulmonary disease: Development of the criteria and validation for use in clinical practice. <i>Pulmonologiya</i> , 2020, 30, 142-150.	0.2	1
833	The concept of control in chronic obstructive pulmonary disease: Development of the criteria and validation for use in clinical practice. <i>Pulmonologiya</i> , 2020, 30, 135-141.	0.2	2
834	Impact of gender on chronic obstructive pulmonary disease outcomes: a propensity score-matched analysis of a prospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1154-1163.	0.7	1
835	Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial. <i>ERJ Open Research</i> , 2021, 7, 00475-2021.	1.1	5
836	Individual trajectory-based care for COPD: getting closer, but not there yet. <i>ERJ Open Research</i> , 2021, 7, 00451-2021.	1.1	2
837	Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease. <i>Cureus</i> , 2021, 13, e19168.	0.2	0
838	Plant-based drug delivery systems in respiratory diseases. , 2020, , 517-539.		4

#	ARTICLE	IF	CITATIONS
839	Pulmonary Airway Disease. , 2020, , 185-208.		0
841	COPD Phenotyping. Respiratory Medicine, 2020, , 225-239.	0.1	0
842	Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity. Respiratory Research, 2020, 21, 21.	1.4	9
843	The Burden of Cough and Phlegm in People With COPD: A COPD Patient-Powered Research Network Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 49-59.	0.5	8
846	The role of pulmonary rehabilitation in the prevention of exacerbations of chronic lung diseases. , 0, , 224-246.		0
848	NEUTROPHIL TO LYMPHOCYTE RATIO AS A MARKER OF ACUTE EXACERBATION AND DISEASE SEVERITY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. , 2020, , 46-47.		0
849	Nipping it in the bud: An inspiring mission for prevention and management of COPD. Journal of Thoracic Disease, 2012, 4, 102-5.	0.6	8
850	Chronic obstructive pulmonary disease. Indian Journal of Medical Research, 2013, 137, 251-69.	0.4	41
851	A role of indacaterol in chronic obstructive pulmonary disease management: a turning point or crossroads?. Journal of Thoracic Disease, 2013, 5, 378-80.	0.6	0
852	Pulmonary function tests and computed tomography lung attenuation in chronic obstructive pulmonary disease. Journal of Thoracic Disease, 2015, 7, 1882-4.	0.6	0
853	Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 680-9.	0.7	7
854	Impact of Comorbid Ischemic Heart Disease on Short-Term Outcomes of Patients Hospitalized for Acute Exacerbations of COPD. Tanaffos, 2015, 14, 165-71.	0.5	8
855	Cigarette Smoke and DNA Cleavage Promote Lung Inflammation and Emphysema. Transactions of the American Clinical and Climatological Association, 2017, 128, 222-233.	0.9	10
856	Implications of the GOLD COPD Classification and Guidelines. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 14S-18S.	0.6	1
857	Changes in health-related quality of life as a marker in the prognosis in COPD patients. ERJ Open Research, 2022, 8, 00181-2021.	1.1	4
858	Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD. Frontiers in Medicine, 2021, 8, 761767.	1.2	5
859	T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2022, 58, 595-600.	0.4	5
860	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	0.9	2

#	ARTICLE	IF	CITATIONS
861	CT pectoralis muscle area is associated with DXA lean mass and correlates with emphysema progression in a tobacco-exposed cohort. <i>Thorax</i> , 2021, , thoraxjnl-2021-217710.	2.7	9
862	The Effect of <i>Ocimum basilicum</i> L. and Its Main Ingredients on Respiratory Disorders: An Experimental, Preclinical, and Clinical Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 805391.	1.6	17
863	Physical and mental health profile of patients with the early-onset severe COPD phenotype: A cross-sectional analysis. <i>Clinical Nutrition</i> , 2022, 41, 653-660.	2.3	0
864	Metabolomics of COPD Pulmonary Rehabilitation Outcomes via Exhaled Breath Condensate. <i>Cells</i> , 2022, 11, 344.	1.8	9
865	Self-management interventions for people with chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2023, 2023, CD002990.	1.5	39
866	Optimism is associated with respiratory symptoms and functional status in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2022, 23, 19.	1.4	1
867	Improved Detection of Chronic Obstructive Pulmonary Disease at Chest CT Using the Mean Curvature of Isophotes. <i>Radiology: Artificial Intelligence</i> , 2022, 4, e210105.	3.0	2
868	Chest <scp>CT</scp>â€assessed comorbidities and allâ€cause mortality risk in <scp>COPD</scp> patients in the <scp>BODE</scp> cohort. <i>Respirology</i> , 2022, 27, 286-293.	1.3	26
870	Phenotyping Cardiopulmonary Exercise Limitations in Chronic Obstructive Pulmonary Disease. <i>Frontiers in Physiology</i> , 2022, 13, 816586.	1.3	3
871	Increased hospitalizations and economic burden in COPD with bronchiectasis: a nationwide representative study. <i>Scientific Reports</i> , 2022, 12, 3829.	1.6	7
872	Expiratory flow limitation in a cohort of highly symptomatic COPD patients. <i>ERJ Open Research</i> , 2022, 8, 00680-2021.	1.1	1
873	Asthma-COPD Overlap. <i>Current Pulmonology Reports</i> , 2022, 11, 1-14.	0.5	1
874	Bronchiectasis and Chronic Obstructive Pulmonary Disease Overlap Syndrome. <i>Clinics in Chest Medicine</i> , 2022, 43, 61-70.	0.8	6
875	Determinants of Pulmonary Emphysema Severity in Taiwanese Patients with Chronic Obstructive Pulmonary Disease: An Integrated Epigenomic and Air Pollutant Analysis. <i>Biomedicines</i> , 2021, 9, 1833.	1.4	3
876	The use of treatable traits to address COPD complexity and heterogeneity and to inform the care. <i>Breathe</i> , 2021, 17, 210118.	0.6	11
877	Review of recent lung biomarkers of potential harm/effect for tobacco research. <i>F1000Research</i> , 0, 10, 1293.	0.8	1
878	Integrated Disease Management for Chronic Obstructive Pulmonary Disease in Primary Care, from the Controlled Trial to Clinical Program: A Cohort Study. <i>International Journal of COPD</i> , 2021, Volume 16, 3449-3464.	0.9	5
880	CD19 and POU2AF1 are Potential Immune-Related Biomarkers Involved in the Emphysema of COPD: On Multiple Microarray Analysis. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 2491-2507.	1.6	4

#	ARTICLE	IF	CITATIONS
881	Distributions and trends of the global burden of COPD attributable to risk factors by SDI, age, and sex from 1990 to 2019: a systematic analysis of GBD 2019 data. <i>Respiratory Research</i> , 2022, 23, 90.	1.4	33
882	COPD and asthma overlap with bronchiectasis. , 0, , 167-185.		0
883	The Current and Future Role of Technology in Respiratory Care. <i>Pulmonary Therapy</i> , 2022, 8, 167-179.	1.1	7
884	Multimorbidity in Elderly Patients with Chronic Obstructive Pulmonary Disease: Stop Smoking! Go Exercise?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 7-8.	2.5	4
889	Role of Short-Chain Fatty Acids Produced by Gut Microbiota in Innate Lung Immunity and Pathogenesis of the Heterogeneous Course of Chronic Obstructive Pulmonary Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4768.	1.8	22
890	CT-Based Commercial Software Applications: Improving Patient Care Through Accurate COPD Subtyping. <i>International Journal of COPD</i> , 2022, Volume 17, 919-930.	0.9	4
891	A Retrospective, Descriptive Study of Dyspnea Management in a Multidisciplinary Interstitial Lung Disease Clinic. <i>American Journal of Hospice and Palliative Medicine</i> , 2022, , 104990912210964.	0.8	1
892	PREVALENCE OF CARDIOVASCULAR COMORBIDITIES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SUBURBAN AREAS OF SOUTH-WEST INDIA. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 72-75.	0.3	0
893	Characteristics of Bronchiectasis Associated with Chronic Obstructive Pulmonary Disease. <i>Open Respiratory Medicine Journal</i> , 2022, 16, .	1.3	0
894	Race and Sex Differences in Mortality in Individuals with Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1661-1668.	1.5	4
897	Sex Differences in the International Primary Care Airways Group Questionnaire for Screening of Chronic Obstructive Pulmonary Disease: A Retrospective, Cross-Sectional Study. <i>International Journal of COPD</i> , 0, Volume 17, 1467-1476.	0.9	1
898	How to Utilize CAT and mMRC Scores to Assess Symptom Status of Patients with COPD in Clinical Practice?. <i>Medeniyet Medical Journal</i> , 2022, 37, 173-179.	0.4	7
899	Increased exploration and hyperlocomotion in a cigarette smoke and LPS induced murine model of COPD: linking pulmonary and systemic inflammation with the brain. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 0, , .	1.3	7
900	The Amplification of Symptoms in the Medically Ill. <i>Journal of General Internal Medicine</i> , 2023, 38, 195-202.	1.3	7
901	Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET. <i>International Journal of COPD</i> , 0, Volume 17, 1703-1713.	0.9	13
902	Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2023, 20, 38-46.	1.5	7
903	Physiological responses and adaptations to exercise training in people with or without chronic obstructive pulmonary disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e065832.	0.8	2
904	Change in individual chronic obstructive pulmonary disease assessment test item scores after short-term bronchodilator therapy and its impact on exacerbation in treatment-naïve patients with chronic obstructive pulmonary disease. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211142.	1.1	1

#	ARTICLE	IF	CITATIONS
905	Editorial: The heterogeneity in COPD phenotypes. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
906	Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD). <i>Journal of Clinical Medicine</i> , 2022, 11, 4886.	1.0	0
907	Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. <i>Lancet</i> , The, 2022, 400, 921-972.	6.3	188
908	Impact of Comorbidities on the Management Outcome of Acute Exacerbation of COPD. , 2021, 7, 62-67.		0
909	Hospital-Level Care at Home for Patients With Acute Respiratory Disease. <i>Chest</i> , 2023, 163, 891-901.	0.4	6
910	Clinical and functional characteristics of patients with chronic obstructive pulmonary disease and bronchiectasis: results of a 10-year prospective observational study. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 54.	0.2	0
911	COPD: Providing the right treatment for the right patient at the right time. <i>Respiratory Medicine</i> , 2022, , 107041.	1.3	1
912	Stratification of COPD patients towards personalized medicine: reproduction and formation of clusters. <i>Respiratory Research</i> , 2022, 23, .	1.4	1
914	Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
915	Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer. <i>Biomedicines</i> , 2023, 11, 448.	1.4	7
916	Treatment, diagnostics, and management of chronic obstructive pulmonary disease in women. <i>Pulmonologiya</i> , 2023, 33, 76-83.	0.2	0
917	Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β_2 -Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. <i>International Journal of COPD</i> , 0, Volume 18, 231-245.	0.9	0
918	Chronic Obstructive Pulmonary Disease and Its Effect on Red Blood Cell Indices. <i>Cureus</i> , 2023, , .	0.2	1
919	Inter-relationships among neutrophilic inflammation, air trapping and future exacerbation in COPD: an analysis of ECOPD study. <i>BMJ Open Respiratory Research</i> , 2023, 10, e001597.	1.2	3
920	Identifying chronic obstructive pulmonary disease from integrative omics and clustering in lung tissue. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3